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Abstract and Keywords 
 The purpose of this thesis was to explore the role of the sympathetic nervous 
system (SNS) in hindlimb vasomotor control during the development of hypertension 
(HT). Using an animal model of essential HT (the spontaneously hypertensive rat [SHR]) 
we demonstrated that neuropeptide Y (NPY) and the Y1 receptor (Y1R) play a greater 
role in modulating hindlimb hemodynamics in the early stages of HT compared to 
normotensive controls (Wistar Kyoto [WKY]). Hindlimb vascular mechanics 
(compliance [C] and viscoelasticity [K]) were assessed using a modified Windkessel 
model developed in our laboratory. The hindlimb mechanics did not appear to be 
regulated by NPY or the Y1R specifically, but the SNS did appear to regulate the 
hindlimb mechanics in both SHRs and WKY animals. The use of female animals in 
physiologic research is limited, thus the role of the SNS in developing HT in females is 
unknown. Finally, differences in the hemodynamic and hindlimb vascular mechanics 
between male and female animals were examined. Female animals exhibited augmented 
MAP and HR relative to males in conjunction with greater stiffness and viscoelasticity in 
both SHR and WKY animals. Female SHRs also appeared to lose SNS control over the 
stiffness and viscoelastic properties of the hindlimb vascular bed, while male SHRs 
maintained this control. These sexually dimorphic characteristics provide evidence for a 
novel proposed mechanism of cardiovascular regulation in young female rats. 
Keywords: Compliance, Conductance, Hexamethonium Bromide, Modified Windkessel 
Model, Pulse Wave Velocity, Resistance, Sexual Dimorphism, Spontaneously 
Hypertensive Rats, Viscoelasticity, Wistar-Kyoto Rats 
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Epigraph 
  
 
 
 
‘I love fools’ experiments. I am always making them.’ 
Charles Darwin 
(1809 ‒ 1882) 
 
 
‘It is not the mountain we conquer but ourselves.’ 
Sir Edmund Hillary 
(1919 – 2008) 
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Chapter 1 ‒ Review of the Literature 
  
 
2 
1.1 Introduction 
The mechanisms governing the distribution of blood flow throughout the body are 
numerous and complex. The methods utilized for blood flow distribution include short-
term (e.g., beat-to-beat) fluctuations in heart rate and cardiac contractility, to more 
continuous changes in the diameter of blood vessels and, in some cases, morphologic 
changes in the mechanics and structure of vascular tissue. In most cases the sympathetic 
nervous system (SNS) is essential in regulating these processes.  
Hypertension (HT) is a chronic medical condition that is pervasive in many 
industrialized nations (145). The complex etiology of the condition makes it difficult to 
manage with medications, and chronic HT is an independent risk factor for many 
cardiovascular diseases including myocardial infarction, atherosclerosis, and stroke (13; 
58; 136; 156). Hypertension has also been implicated in other pathological conditions 
such as metabolic syndrome (11; 79). The physiologic mechanisms contributing to HT 
are numerous, and an important role for the SNS is clear; however, the reasons why the 
SNS, and other systems, propagate HT remain unclear. 
This thesis focuses on the integration of the nervous and cardiovascular systems 
and how the two are regulated in normotensive and hypertensive rats. It is important to 
note that most of the comparisons made here have been done in very young animals (7 
weeks of age). This is a critical point to emphasize, as it exposes differences in 
neurovascular coupling as the HT is developing (91; 132). Much of the work describing 
alterations in HT has been done in established HT; when the blood pressure has been 
elevated for a time. Examining differences in neurovascular regulation as HT develops 
may expose novel mechanisms which act to augment the blood pressure. Emphasis will 
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be placed on the mechanical properties of the vasculature in normotension and 
developing HT, and sex differences in neurovascular regulation of both normotensive and 
hypertensive animals will be examined.  
1.2 Outline of Thesis  
This thesis outlines our attempts to understand the integration of the sympathetic 
nervous system (SNS) and cardiovascular systems in the early stages of hypertension 
(HT). The experiments outlined were designed to examine the working hypothesis that 
the sympathetically-mediated mechanical and biochemical properties of the vasculature 
would be altered very early in the development of HT, with specific changes in 
neuropeptide Y (NPY) signaling through the Y1 receptor (Y1R). It has been demonstrated 
that although female rats possess NPY and the Y1R, this pathway is not utilized in the 
control of hindlimb hemodynamics such as it is in male animals (74; 75). Therefore, it 
was hypothesized further that alterations in sympathetic control in female hypertensive 
rats would be different than those observed in males. To address these hypotheses, the 
integration of the SNS and cardiovascular systems was examined by combining 
physiological data in the form of systemic and regional hemodynamics, molecular 
markers of sympathetic signaling, and mathematical modeling of the mechanical 
properties of the hindlimb. This section outlines the rationale for each of the subsequent 
chapters, and, hopefully, bridges them creating a more cohesive document.  
Chapter 2 entitled “Enhanced regulation of hindlimb vascular control by 
neuropeptide Y during the development of hypertension” was designed to assess the role 
of the SNS in the hemodynamic responses of exogenous adrenergic receptor (α-AR) and 
Y1R agonists in 3-7 week old male SHR animals and WKY controls. It was 
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hypothesized that altered neurovascular regulation would occur early in the development 
of HT with changes that include modifications to the Y1R and/or α-AR regulation. If so, 
then any differences observed in SHR animals in the response to exogenous sympathetic 
agonists would reflect alterations to the cellular signaling which might contribute to the 
development of HT.  
Chapter 3 entitled “Y1 receptor versus sympathetic control of hindlimb vascular 
stiffness in spontaneously hypertensive rats” utilized a modeling approach to quantify the 
mechanical properties of the vasculature in both normotension and hypertension. We 
employed this technique to supplement data from chapter 2 in order to examine the role 
of the Y1R in particular, and the SNS in general, in mediating vascular stiffness in HT. 
We tested the specific hypothesis that Y1R activation, and the general hypothesis that 
sympathetic activation, would contribute to vascular stiffness in the developmental stages 
of HT. Should the SNS regulate the stiffness of the vasculature, increased stiffness would 
augment blood pressure and exacerbate HT. Increased vascular stiffness is a hallmark of 
established HT (81); however, whether the stiffness contributes to, or is a consequence 
of, HT is debated (65). Examining the mechanical properties of the vasculature during the 
early stages of HT should provide a more complete understanding of the role of vascular 
mechanics in augmenting blood pressure.  
Sex-based differences exist in sympathetic cardiovascular regulation (74-76) and 
the prevalence and severity of HT (5; 67). Chapter 4, entitled “Sympathetic contribution 
to peripheral vascular stiffness in young female spontaneously hypertensive rats”, was 
designed to examine the role of the SNS in regulating the mechanical properties of the 
hindlimb in female animals. Detailed examinations of specific agonist/antagonist control 
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were not performed as previous research indicates females do not utilize the NPY system 
in vascular regulation (74; 75), and chapter 3 suggests that the regulation of the 
mechanical properties are not under Y1R control but, rather, are related to sympathetic 
neural activity per se. Therefore, we tested the hypothesis that vascular stiffness and 
viscoelasticity are under neurogenic control in females as they appear to be in males. But, 
because females appear to rely on different mechanisms of cardiovascular control, 
differences in HT would be manifest in the mechanical properties of the vasculature.  
Finally, chapter 5 “Evidence for sexual dimorphism in sympathetic control of 
vascular function” explores the sex-associated differences observed in hemodynamic and 
hindlimb vascular mechanics in both normotensive and hypertensive rats. These 
differences were evident during data analysis and warrant some discussion. This chapter 
also hypothesizes a mechanism as to why these differences may exist.  
The dissertation concludes in chapter 6 with a general discussion about the 
implications for the body of work as a whole. The role of NPY and the SNS in 
cardiovascular regulation are highlighted, as are the differences in cardiovascular control 
between male and female animals. Limitations of the research are addressed, and areas 
where this line of research can be continued are proposed. 
 This dissertation embodies a series of studies which examine the mechanical 
and/or biochemical alterations that occur in the early stages of HT. The role of the SNS in 
general, and NPY in particular, are investigated as is the role of sex in moderating 
differences observed.  
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1.3 Mechanisms of Sympathetic Control 
The SNS relies on three chemical transmitters to communicate with peripheral 
tissues. Adenosine triphosphate (ATP), norepinephrine (NE) and neuropeptide Y (NPY) 
are synthesized, stored and released from neurons of the SNS and act via specific 
receptors to elicit discrete responses. Of the sympathetic neurotransmitters, NE has 
received the most consideration, but a role for NPY in baseline vasomotor control has 
emerged (74-76). ATP, NE and NPY exert both acute and chronic effects on the 
vasculature. Acutely, all three transmitters elicit vasoconstriction of vascular smooth 
muscle cells (VSMCs), which acts to increase vascular resistance (18; 103; 179). 
Chronically, these molecules are mitogenic and stimulate VSMCs growth and 
proliferation also known as vascular remodeling (121; 170; 176). Vascular remodeling is 
a characteristic of HT, typically seen as a thickening and stiffening of the vascular wall 
(see below) (34; 48; 104). 
The SNS regulates the distribution of blood throughout the body by acting on a 
level of the vasculature known collectively as resistance vessels. By altering the diameter 
of the resistance vessels the SNS increases the resistance to flow, and therefore limits 
tissue perfusion (118). Tissues that require an increase in blood flow, due to increased 
metabolic demand, release a host of metabolic vasodilators that compete with, or directly 
inhibit, the constrictor effect of the SNS (60; 83). 
ATP, a purine nucleotide primarily known for its role as a co-enzyme, fueling 
metabolic processes through the cleavage of its high energy phosphate bonds (84), is 
released from synaptic vesicles with NE and NPY and is responsible for excitatory 
junction potentials (EJPs). EJPs are minute depolarizations that occur in a postjunctional 
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cell (often VSMCs) following a single ‘pulse’ from a prejunctional neuron. These EJPs 
are rapid and can summate to initiate a mechanical contraction. However, EJPs are rapid 
and transient, and are often followed by a slow depolarization that is mediated by NE 
((144) see below). ATP acts through two types of receptors (P2X1-7 and P2Y1, 2, 4, 6, 11, 12, 
13,14). P2X receptors are fast inotropic ligand-gated ion channels, and P2Y receptors are 
part of the G protein-coupled receptor (GPCR) superfamily, which are described below. 
P2X receptors are found on neurons and smooth muscle cells; while, P2Y receptors can 
be found on most cells in the body (21; 22).  
The archetypal neurotransmitter of the SNS is NE. NE is a catecholamine that is 
synthesized from the amino acid tyrosine through a series of enzymatic reactions. NE is 
released from sympathetic varicosities in a Ca2+ dependent manner following the 
depolarization of the membrane by an action potential. NE exerts its actions on post 
synaptic cells through α- and β-adrenergic receptors (AR) (52). There are two types of α-
ARs; α1- and α2-ARs. α1-ARs are primarily found on VSMCs and elicit cellular 
contraction (tissue vasoconstriction) through a GPCR mechanism. α2-AR are found 
primarily pre-junctionally on nerve terminals, where they inhibit vesicle release through a 
negative feedback mechanism. Post-junctionally α2-ARs signal vasoconstriction (53).  
While three β-ARs have been identified, cloned and classified as GPCRs (97), the 
majority of NEs effect in the vascular system is done through the β2-AR. Stimulation of 
the β2-ARs, which are primarily found in arterioles of skeletal muscle, will result in 
vasodilation (14). It should be noted, that the β1-AR is found in the heart, and increases 
heart rate and contractility. While these inotropic and chronotropic effects will factor into 
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vascular regulation, it is the direct role of the α1-AR on the diameter of the blood vessels 
supplying a vascular bed that is the primary determinant of tissue perfusion (148).  
NPY exerts it actions through a family of GPCRs called Y-receptors. Six 
members of the Y-receptor family have been cloned or postulated; however, the 
dominant receptors mediating cardiovascular responses are the Y1 and Y2 receptors (Y1R 
and Y2R, respectively) (3; 66; 120). The Y1R is primarily found on VSMCs and 
preferentially binds NPY (30; 107; 183) eliciting vasoconstriction, potentiation of NE, 
and mitogenesis (2; 76; 105; 181). Y2Rs are found in abundance on sympathetic and 
parasympathetic nerve terminals (146; 157) and preferentially bind an enzymatically 
truncated NPY molecule. NPY is degraded by aminopeptidase P (APP) and dipeptidyl 
peptidase IV (DPP IV) in the neurovascular cleft to produce the biologically active NPY3-
36 and NPY2-36, respectively, both of which act via the Y2R to reduce vesicular release in 
a negative feedback manner (3; 120; 124; 125). 
Many of the vascular receptors mentioned above are classified as G-protein 
coupled receptors, or GPCR. GPCR are members of the rhodopsin-like superfamily of 
receptors characterized by a 7-transmembrane receptor linked to a guanine nucleotide-
binding protein (G-protein) (101). The G-protein is comprised of α-, β-, and γ-subunits 
each of which have isoforms resulting in immense diversity (20; 45). Ligand specificity 
occurs at the 7-transmembrane receptor domain where activation (from ligand binding) 
produces a conformational change in the Gα-subunit resulting in the substitution of a 
guanosine diphosphate (GDP) molecule for guanosine triphosphate (GTP). GTP binding 
releases the tightly associated Gβ- and Gγ-subunits (the βγ-complex) allowing both the 
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Gα-subunit and the βγ-complex to activate targets, thus commencing intracellular 
signaling (59; 78). 
GPCRs are classified by the actions of the Gα-subunit; however, signaling by the 
βγ-complex is now accepted (129). Four main classes of Gα-subunits have been 
identified. They include, Gαs which stimulates Adenylyl Cyclase (AC), Gαi which 
inhibits AC, Gαq which increases the activity of phospholipase C (PLC), and Gα12/13 
which activates the Rho Family of GTP-ases (101; 129).  
α1-ARs and some P2Y (P2Y1, 2, 4, 6, 11 and 14) receptors contain Gαq-subunits 
culminating in the activation of PLC. PLC enzymatically cleaves the phospholipid 
phosphatydlinositol 4,5-bisphosphate (PIP2) into the biologically active diacyl glycerol 
(DAG) and inositol 1,4,5-triphosphate (IP3) (114). IP3 binds to the InsP3-receptor on the 
sarcoplamsic reticulum resulting in the mobilization of Ca2+ (53). DAG, in turn, activates 
Protein Kinase C (PKC) which, in VSMCs, leads to the phosphorylation of myosin light 
chain phosphatase (MLCP). Phosphorylation of MLCP reduces its activity, resulting in 
sustained Ca2+ sensitization of myosin light chain 20 (MLC20). The sustained Ca2+ 
sensitization of MLC20 allows for continued actomyosin coupling, and in conjunction 
with increased Ca2+ mobilization (from IP3), leads to cellular contraction. 
α2-AR’s, some P2Y (P2Y4, 12, 13) receptors and all Y-receptors contain the Gαi-
subunit. The β-ARs contain Gαs, which acts in opposition to Gαi. Gαs activates AC (26) 
which converts ATP into cyclic-adenosine monophosphate (cAMP). Increases in the 
concentration of cAMP activate cAMP-dependent protein kinase (protein kinase A; 
PKA). PKA phosphorylates a myriad of cellular targets including the sarco/endoplasmic 
reticulum Ca2+ ATP-ase (SERCA) and myosin light chain kinase (MLCK). Activation of 
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SERCA reduces intracellular Ca2+, while phosphorylation of MLCK reduced its activity 
allowing MLCP to reduce the affinity of MLC20 for Ca2+. Both of these events will lead 
to reduced actomyosin coupling and relaxation of VSMCs. Inhibition of AC (by Gαi) 
prevents the activation of PKA, ultimately leading to increased intracellular Ca2+ 
concentrations and contraction of VSMCs (2; 20; 86; 115). 
The cellular pathways outlined above are required to elicit acute sympathetically 
mediated vasoconstriction in blood vessels. Other more chronic sympathetically mediated 
GPCR actions have been identified (40; 41). Both NE and NPY have been shown to 
activate a variety of mitogen activated protein kinases (MAPKs) which play an important 
role in mitogenesis, proliferation and migration of VSMCs (40; 87; 116; 120; 127; 134; 
170; 170; 183). Because the targets of second messenger cascades are numerous, cross 
talk between many GPCRs signaling cascades occurs, and in many cases leads to the 
activation of various MAPK pathways including extracellular signal-regulated kinases 
(ERK) 1 and 2 (ERK1/2), p38, and c-Jun N-terminal kinases (JNK) (12; 41; 128; 177). 
These pathways lead to gene transcription, cellular proliferation and ultimately vascular 
remodeling (see below). 
1.4 The Sympathetic Nervous System and Hypertension 
Hypertension is a multi-faceted condition that has many complex and diverse 
etiologies. Heightened SNS activity is a prominent feature of HT (25; 104; 139; 178) that 
begins early in life (24; 48; 169). The underlying cause of augmented SNS activation 
leading to HT remains unknown (54); however, the mechanisms involved include 
defective baroreceptor autoregulation, increased hypothalamic response to environmental 
stimuli, stimulation of renal afferent sympathetics, and elevated thoracolumbar 
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sympathetic activity (79). Regardless of the cause, the heightened SNS activity produces 
chronically elevated vascular resistance (R) (10; 71; 132) and exposes the vasculature to 
trophic factors which can cause inappropriate tissue remodeling (10; 168). This thesis 
examines the impact of heightened SNS activity on vascular structure and function as a 
critical feature in the early stages of HT.  
Detailed examinations of the hemodynamic and phenotypic alterations during the 
development of HT have been made (4; 122). Use of the spontaneously hypertensive rat 
(SHR) has identified many underlying pathologies that lead to the development of HT, 
including alterations in the Renin-Angiotensin System, renal physiology and the SNS 
(110; 155; 156). HT develops early in the life of SHR animals (approximately 5-weeks of 
age) and elevated sympathetic outflow has been implicated in this early pathology. In the 
SHR model, sympathetic innervation of several vascular beds occurs very soon after 
birth, before the development of hypertension (64) and neonatal sympathectomy 
consistently prevents the development of high blood pressure in SHR (90; 153). Thus, 
pre-hypertensive SHR animals at age 4-5 weeks have higher interstitial NE levels in 
muscle and fat than their age-matched Wistar-Kyoto (WKY) controls (24). However, 
evidence suggests that this innervation pattern is tissue-specific with little difference in 
the sympathetic activation of the heart in young SHR and WKY animals (64). 
Similarly, evidence indicates that hindlimb vascular remodeling occurs as early as 
4-5 weeks of age in the SHR, and may precede the blood pressure augmentation (85; 132; 
140). This remodeling displayed regional specificity and debate exists as to the specific 
involvement of sympathetic stimuli (91; 140). Furthermore, these studies do not address 
the role of NPY in mediating the vascular remodeling associated with HT at this young 
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age. Indeed, the roles that NPY plays in the regulation of blood pressure, vasomotor 
control and/or vascular mechanics at this critical age are not well understood.  
1.5 Signaling Alterations in Hypertension 
As mentioned, sympathetic hyperactivity is seen regularly in HT (25; 104; 139; 
178). The influence of augmented innervation can be compounded by genetic 
modifications which have been identified in HT (33; 44; 56; 143). These genetic 
modifications lead to an imbalance between constrictor and dilatory signals, and lead to 
increased constriction, augmented vascular resistance and arterial pressure (45; 46; 56; 
143).  
An extremely important step in GPCR signaling is the process of desensitization. 
Desensitization is the mechanism whereby a signaling ‘memory’ is formed (20). If, for 
instance, a cell is exposed to NE, GPCR activation and 2nd messenger cascades are 
initiated (as outlined above). In addition to the target molecules which regulate 
vasoconstriction, another a group of molecules termed GPCR kinases (GRKs), are 
activated which lead to the phosphorylation of the GPCR. A phosphorylated GPCR is 
targeted by β-Arrestin molecules which internalize the GPCR. If the cell is repeatedly 
exposed to a ligand, desensitization is a means by which the cell expresses fewer 
receptors (of that specific ligand). Alternatively, the same mechanism allows a cell to 
express more receptor when low levels of a specific ligand are present (i.e. sensitization) 
(49; 92). A variety of alterations in GRK activity/expression have been associated with 
HT (46; 142). For example, increased expression of GRK2 is often seen in hypertensive 
models. Increased GRK2 leads to increased desensitization of the β2-AR resulting in 
reduced vasodilation, blunted AC coupling and vascular remodeling (36; 61). 
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Additionally, transgenic mice expressing a GRK4 gene isolated from human hypertensive 
patients demonstrated alterations in dopamine stimulated sodium excretion from the 
kidneys, impairments in GRK4 activity and HT (43). 
Genetic alterations in HT have also been observed in the β2-AR (44; 45). The 
primary role of the β2-AR on VSMCs is vasodilation, mediated by Gαs and the activation 
of AC. A number of single nucleotide polymorphisms (SNPs) of the β-AR are associated 
with HT. Both the Arg16Gly and Gln27Glu SNPs have little effect on receptor binding 
affinity or AC activation, but prevent receptor desensitization compared with wildtype 
receptors (17; 55). Additionally, the Thr164Ile SNP results in reduced AC activity and 
impaired Gαs coupling (16). Ultimately, the physiological consequence of these SNPs is a 
blunted vasodilatory response in VSMCs.  
Another type of molecular alteration that occurs in HT is known as signal 
switching (33). The β2-AR typically couples with the Gαs subunit (as described above) to 
elicit vasodilation. In some cases the β2-AR has been shown to couple to Gαi leading to 
MAPK activation (89; 171). The mechanisms that result in signal switching may not be 
pathophysiological, but could be a secondary signaling mode of the β2-AR. If this is the 
case, it underscores our limited understanding of the molecular mechanisms of cellular 
regulation (143). 
1.6 Vascular Mechanics 
 The control of blood flow distribution and blood pressure maintenance in the 
body has many levels of regulation. At the systemic level the SNS plays a vital role in 
distributing blood away from areas of low metabolic demand, while local metabolic 
factors allow for increased blood supply to places where demand is high (7; 31; 113; 
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151). The large elastic arteries in the trunk of the body branch and become muscular 
resistance vessels in the limbs and visceral organs. Distribution of blood flow is primarily 
done through manipulation of the resistance in the vessels feeding a given tissue. 
Resistance to flow is determined by the pressure change across a vascular bed and the 
flow entering the system (117). The relationships between flow, pressure gradients and 
the dimensions of a capillary tube were first established by Jean Leonard Poiseuille (1797 
– 1869). Poiseuille’s equation (126) relates a pressure gradient across a tube with the 
flow, viscosity of the fluid, le d  f the tube: ngth and ra ius o
 ܳ ൌ గ௥
రሺ௉భି௉మሻ
଼ఓ௅
  Equation 1.1  
where Q is the volume flow per unit time, r is the internal radius , P1 – P2 is the pressure 
drop, µ is the viscosity of the blood, and L is the length of the of the tube.  
 To use Poiseuille’s equation, knowledge of the architecture of the vessels is 
needed. This is not always possible to ascertain; however, when considering the vascular 
system as a whole, or one of its regions, the formula can be simplified to relate the 
pressure difference (i.e. arterial ‒ venous pressure) as the product of the flow (Q; i.e. 
cardiac output) and the resistance to flow (R) (117). As the pressure in the venous system 
is sufficiently low, R can be calculated as: 
 ܴ ൌ ெ஺௉
ொ
 Equation 1.2 
where R is the resistance, MAP is the mean arterial pressure and Q is the flow (cardiac 
output systemically, or volume flow in a large peripheral artery). Notice that an increase 
in resistance will cause a drop in flow (if pressure is held constant). In the vascular 
system, the most effective way to change the resistance of a vessel is through the 
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manipulation of the vessel diameter. Poiseuille’s equation dictates that flow (Q) is 
proportional to the radius (r) to the 4th power, so a small change in the diameter of a 
vessel will have profound effects on flow through that vessel. 
 A number of assumptions must be made in order to use Poiseuille’s equation in 
physiologic situations so that flow, pressure and/or resistance can be derived from the 
equations outlined. These assumptions relate to the properties of the blood, blood flow 
and the ‘tube’ in which the flow is traveling. First, it is assumed that the fluid is 
homogeneous and its viscosity is the same at all rates of shear. Blood is, of course, 
composed of particulate matter (cells) suspended in a fluid (plasma). In arteries where the 
radius is sufficiently large compared to the size of red cells, blood behaves as a 
Newtonian fluid, and this assumption holds true. However, these fluid characteristics 
change as the vessels become smaller at the arteriolar level. The second assumption is 
that the liquid does not slip at the wall. This is universally true for liquids, as the friction 
between the wall and the flowing liquid makes the velocity at the wall zero. Assumption 
three dictates that the flow is laminar with the liquid moving parallel to the wall of the 
tube. This assumption is not satisfied in some large vessels where turbulent flow is 
possible (i.e. the aorta). Assumption four is also invalid in large arteries, because the flow 
is not ‘steady’ but is pulsatile and is subject to acceleration and deceleration. The final 
two assumptions deal with the tube in which the flow is occurring. Assumption five states 
that the tube is long compared with the region being studied. This is required to allow for 
laminar flow to develop (assumption three). The final assumption dictates that the tube is 
rigid and the diameter does not vary with internal pressure. Blood vessels are viscoelastic 
structures which distend with an increase in arterial pressure during each heart beat. 
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Some have argued that in many vascular beds the walls are muscular and blood flow is 
sufficiently steady so that the internal diameter does not distend and the application of 
Poiseuille’s equation is permitted (118). This speculation may apply to microvascular 
beds. Yet, the pulsatile mechanics of microvascular beds have not been studied, 
particularly in the context of hypertension. Our laboratory has developed methods to 
study the oscillatory stiffness, viscoelasticity and inertial elements of flow in a vascular 
bed (172-175) and these methods will be used, for the first time, in a rodent model of 
hypertension in the ensuing studies. 
 The assumptions underlying Poiseuille only allow us to approximate the 
physiology of the circulation. Historically, R has been the primary indicator of vascular 
regulation, as a change in resistance is indicative of vessel caliber (23; 135). This 
however, is an estimate at best, as R only reflects the steady state component of blood 
flow and neglects the pulsatile nature of blood flow which violates the assumptions listed 
above. The analogue of R in a pulsatile system is termed impedance (Z) and is given by 
(173; 174): 
 ܼ ൌ ோ
ଵାܴ݅߱ܥ
 Equation 1.3 
where R is resistance, i = √െ1, ω is the frequency of oscillation and C is the compliance 
of the vessel given by: 
 ܥ ൌ ∆௏
∆ሺ∆௉ሻ
  Equation 1.4 
where ΔV is a change in volume and Δ(ΔP) is a change in the pressure gradient. 
Compliance reflects the change in the pressure difference needed to change the volume of 
a system. Increases in C allow for greater volume changes for a given change in the 
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pressure gradient (173). C is the inverse of stiffness, and in many disease states, stiffness 
is used as a clinical marker of disease severity (i.e. pulse wave velocity) (112; 137).  
 To better understand the oscillatory nature of the vascular system it is typically 
modeled as a Windkessel. Windkessel in German means ‘air chamber’ but in respect to 
the vascular system it implies the elastic reservoir created by the aorta and other large 
elastic arteries with increasing pressure from each heart beat. The principle of the 
Windkessel effect is simply the stretching of the walls of large elastic arteries due to the 
ejection of blood from the heart. The stretch of the vessel walls store potential energy 
during systole, allowing for a passive recoil of the elastic lamella of the tunica media 
creating blood flow during diastole (when the heart is relaxed) (108; 118).  
Windkessel models are typically lumped models of the vasculature. Lumped 
models are useful tools for studying the vasculature because vascular networks are 
immensely complex. By representing the entire structure of a vascular network as a single 
tube with the properties of the network as a whole, a “black-box” is created, where the 
relationship between inputs and output is easily understood (173). To adequately model 
the pulsatile nature of skeletal muscle blood flow, it is necessary to include additional 
parameters to Equation 1.3. Equation 1.5 incorporates Equation 1.3 with the addition of 
the viscoelastic properties of the vessel (K), and the inductance (L), representing the 
effects of fluid and vessel wall inertia, both of which are required in series with C (Figure 
1.1) (174):  
 ܼ ൌ ோ
ሾఠ௄஼ା௜ሺఠమܮܥିଵሻሿ
ఠ஼ሺ௄ାோሻା௜ሺఠమ௅஼ିଵሻ
 Equation 1.5 
This model (termed the ‘RCKL’ model) uses measured pressure and flow waveforms 
(Figure 1.2) which are decomposed and averaged into pressure (P; Figure 1.3), and flow 
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harmonics (Q; Figure 1.4) using fast Fourier transformations (15; 158), which can be 
used in Equation 1.6 to calculate impedance: 
 ܳ ൌ ௉
௓
 Equation 1.6 
This is analogous to Equation 1.2 and when combined with Equation 1.5 we are able to 
approximate Q using th rm (Figure 1.3) and Equation 1.7: e measured pressure wavefo
 ܳ ൌ ௉ఠ஼
ሺ௄ାோሻା௜ሺఠమ௅஼ିଵሻ
ோሾఠ௄஼ା௜ሺఠమ௅஼ିଵሻሿ
 Equation 1.7 
 RCKL predicts a flow waveform based on the measured pressure waveform. By 
manipulating the parameters C, K, and L, the calculated flow waveform can be compared 
to a measured flow waveform. When congruency between the measured and calculated 
waveforms is found, the values for C, K, and L represent the properties of the lumped 
vascular bed (Figure 1.5).  
 The lumped properties obtained using the RCKL model, while providing useful 
information about the mechanical properties of a given vascular bed, do have inherent 
limitations which need to be addressed. Primarily, because these properties represent the 
vasculature as a whole, we are unable to ascribe a specific level of the vascular tree to a 
given component of the model (174). Additionally, a large proportion of the resistance in 
the model is generated by resistance arterioles, but it is unclear from the model whether 
or by how much these vessels also contribute to the compliance of the vascular bed. The 
model as it is applied in this thesis only reflects the pressure-flow relationships of the rat 
hindlimb being studied, and do not reflect the vasculature as a whole. Further, as surgical 
interventions were required to obtain the pressure and flow measurements used, the effect 
of anaesthesia and/or the surgery itself in altering the mechanical properties of the 
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vasculature cannot be ruled out. Finally, the four components of this model; resistance, 
compliance, viscoelasticity and inertia, represent an over simplification of a complex 
physiologic system giving us a method to conceptualize the mechanical properties (174).  
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Figure 1.1 – Representation of the RCKL model. Resistance (R) in this lumped modified 
Windkessel model is in parallel with compliance (C), the viscoelastic properties of the 
vessel wall (K), and inductance (L) representing the inertial effects of the blood and 
vessel walls. 
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Figure 1.2 – Data selection used to estimate the mechanical properties of the vasculature 
of the rat hindlimb. ECG (top) arterial blood pressure (middle) and arterial blood flow 
(bottom) are obtained during a representative period of baseline or during a reflex 
maneuver.  
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Figure 1.3 – Averaged pressure waveform from data selection in Figure 1.2. Waveforms 
are averaged in both the time and frequency domain to obtain an average pressure 
waveform. 
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Figure 1.4 ‒ Averaged flow waveform from data selection in Figure 1.2. Waveforms are 
averaged in both the time and frequency domain to obtain an average flow waveform. 
 
  
 
24 
 
 
Figure 1.5 – Measured (solid) and calculated (dashed) flow waveform from the RCKL 
model. The value for resistance (R) is calculated as the mean pressure divided by the 
mean flow. The values for compliance (C), viscoelasticity (K), and inertia (L) shown are 
those that produced the best agreement between the averaged pressure (Figure 1.3) and 
flow (Figure 1.4) waveforms. These values represent the lumped properties of a vascular 
bed. ‘E’ as outlined above represents the error (least square difference) between the 
measured and calculated waveforms.  
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1.7 Vascular Remodeling and Mechanical Alterations in Hypertension 
Increased blood pressure and SNS activity both contribute to the characteristic 
vascular remodeling seen in HT (34; 48; 104; 164). Both hemodynamic forces acting 
from within the vessel and extrinsic factors that act on the vessel wall factor into the 
remodeling process (180). Debate exists as to whether vascular remodeling occurs before 
blood pressure rises, or occurs as a consequence of HT (65). Many factors contribute to 
vascular remodeling; however, this section outlines only those aspects which are 
mediated by mechanical or sympathetic mechanisms. For detailed reviews of different 
aspects of vascular remodeling see (94; 131; 180). 
Mechanical stresses have the ability to alter the composition of biological tissues. 
Changes in volume, shear stress and stretch have all been documented to alter the 
structure of the vessel wall (69). This section will highlight augmented blood pressure 
causing an increase the circumferential stress within the wall of the vessel. The increased 
wall stress is sensed by vascular cells (likely via integrins linked to cytoskeletal 
components (106)), and stimulates a phenotypic change in VSMCs in an attempt to 
normalize the wall tension (described below). 
The relationship between arterial pressure and the architecture of a blood vessel is 
defined by the Law of Laplace (23; 163): 
 ࢀ ൌ ࡼൈ࢘࢏
ࢎ
 Equation 1.8  
where T is the wall tension (wall stress), P is the distending (arterial) pressure, ri is the 
internal radius and h is the wall thickness. Using the Law of Laplace we are able to 
conceptualize the physiologic mechanisms at work in the vessel wall that act to counter 
the increased wall tension created by augmented pressure. Acutely, an increase in 
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distending pressure will cause an increase in myogenic constriction, thereby reducing ri 
in an attempt to restore the wall stress; but, at the same time increasing vascular 
resistance (see Poiseuille’s equation) resulting in a positive-feedback mechanism which 
ultimately increases blood pressure (65; 73). 
Chronically, vascular tissue remodels as a compensatory mechanism to normalize 
wall stress. Hypertrophy and hyperplasia occur in VSMCs following a phenotypic shift 
from one of constriction to synthesis. VSMCs begin to divide and excrete extracellular 
matrix. The excretion of extracellular matrix proteins alters the proportions of 
components of the vessel wall and can perpetuate the remodeling process, as it has been 
shown in vitro that VSMCs are sensitive to the makeup of the medium on which they are 
grown (68; 116; 152). In this instance, vascular remodeling is a consequence of HT (1; 
19). 
Extrinsic regulators of vascular remodeling are numerous and include angiotensin 
II, nitric oxide, matrix metalloproteinases, inflammatory mediators, sex hormones, and 
sympathetic neurotransmitters (2; 40; 50; 131; 147; 167). The vasculature is chronically 
exposed to these factors, with the exception of sex hormones which have a more 
pronounced role following puberty. The cumulative activation of vascular cells is thought 
to initiate vascular remodeling in the absence of augmented blood pressure. As outlined 
in Section 1.3 activation of MAPKs can lead to gene transcription, protein translation and 
ultimately vascular remodeling. The processes which result in vascular remodeling are 
not exclusive to VSMCs, as endothelial cells (ECs) and adventitial fibroblasts (AFB) 
express a number of the same receptors as VSMCs. Importantly for the remodeling 
process AR and Y-receptors on AFB stimulate cell growth and protein synthesis, further 
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altering the makeup of the extracellular matrix and facilitating VSMC activation and 
migration (42; 68; 116; 152). The activation of vascular cells can occur independently of 
arterial pressure causing a remodeling that occurs before the pressure is augmented (85; 
132; 140).  
Both of the mechanisms described independently cause vascular remodeling, but 
they can also act in conjunction with one another to accelerate the remodeling process. 
Thus, the study of vascular remodeling in HT is immensely complex. Multiple processes 
converge to elicit the transformation of the vessel wall (65; 133; 180). Compounding the 
situation in HT is the continual augmentation of blood pressure, and associated co-
morbidities. Functionally, it is the narrowing of the lumen of blood vessels and the 
thickening of the vessel wall which promote HT. A narrower lumen increases the 
resistance to flow thus adding to the increased blood pressure (63; 165). Thickening of 
the arterial wall acts to stiffen the vessel which adds to HT by increasing the afterload on 
the left ventricle (119). Afterload is dependent on systemic pressure and reflects the force 
needed to open the aortic valve. Afterload is augmented by the summation of systolic 
pressure (generated by the left ventricle) and pressure waveforms reflected from the 
periphery. Reflected pressure waveforms arise from sites of incongruity (i.e. bifurcations) 
in the peripheral vasculature. In a healthy arterial system, wave reflections reach the aorta 
during diastole which adds little to the workload of the heart (as the aortic valve is 
closed). Stiffer blood vessels transmit both outgoing and reflected pressure waveforms 
faster, allowing the reflected waveform to return to the aorta during systole and forces the 
heart to work harder to expel blood (81; 119; 161; 162).  
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Details of the mechanisms responsible for vascular remodeling are being 
elucidated to determine whether augmented pressure leads to vascular remodeling, or the 
remodeling initiates the rise in pressure (35; 65; 94; 164). Indeed both scenarios are 
evident (63; 70), and likely occur in concert to generate cardiovascular dysfunction. 
Clinical assessment of vascular stiffening is typically measured using either pulse wave 
velocity, and/or arterial compliance (8; 72). Pulse wave velocity and arterial compliance 
are useful tools to assess either ‘central’ or ‘point’ arterial stiffness, respectively, but 
neglect the contribution of the microcirculation in mediating stiffness. An emerging 
hypothesis suggests that the microvasculature is the site where remodeling begins leading 
to changes in central arteries, and ultimately HT or cardiovascular disease (88; 96), 
although this has not been established. Thus, the functional and morphologic bases of the 
vascular properties in the developmental stages of HT are required. The studies in this 
dissertation emphasize vascular remodeling using both functional and morphologic 
measurements, with emphasis on peripheral hindlimb vascular beds and systemic 
vascular measures that directly relate to stiffness.  
1.8 Estrogen, the Vascular System and Hypertension 
 Estrogens, androgens and progestogens, the sex hormones, are groups of 
structurally-related steroid hormones which exert distinct actions throughout the body. 
Estrogens have received the most attention in the literature and have been linked to both 
beneficial and adverse cardiovascular outcomes (111; 119). Of the three estrogens: 
estradiol, esterone, and estriol, estradiol (E2) is the most biologically available and is has 
the greatest influence on tissue function and structure (141). This section examines the 
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physiologic role of E2 in vascular tissue, and will examine the evidence for and against 
protective effects of E2. 
A myriad of discrete physiologic effects have been identified for E2 outside of 
reproductive tissues. Specifically in vascular tissue (predominantly ECs and VSMCs) 
both rapid (acute) and genomic (chronic) effects have been identified and warrant some 
discussion (29; 154). Because estrogen is derived from cholesterol, it readily diffuses 
through the plasma membrane and can bind to the two related estrogen receptors (ER) 
that have been identified and cloned. The ERα and ERβ are members of a nuclear 
receptor superfamily of ligand- or hormone-dependent transcription factors. Both 
receptors display high homology, similar affinity for E2, and coexpression in many 
tissues (32; 109). However, distinct expression patterns have been documented, and 
where co-expression exists, ERβ has been suggested to modulate the actions of ERα 
(159).  
Estradiol exerts a host of acute effects in vascular tissues. These effects occur in 
the order of seconds to minutes and are initiated far too quickly to involve gene 
transcription (102; 130). These effects were initially attributed to a membrane bound 
subpopulation of the ERα (38), but many of the acute responses to E2 have now been 
ascribed to a novel GPCR known as GPR30. It should be noted that debate as to whether 
GPR30 is in fact an estrogen receptor exists (95; 123). Acutely E2 typically elicits 
endothelial dependant vasodilation. The mechanism has been linked to GPR30 
stimulation of endothelial nitric oxide synthase (NOS). Additionally, acute activation of 
GPR30 by E2 has been linked to activation of PKA, and phosphoinositide 3-kinase (PI3) 
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kinase. Concurrent activation of MAPKs, Raf and Src kinases leads to genomic 
translation and thereby linking the acute and chronic effects of E2 (47; 102).  
As with many GPCRs, 2nd messenger signaling cascades initiated by GPR30 can 
activate pathways that promote both constriction and relaxation depending on the cell 
type on which they are expressed. For example, E2 stimulated activation of PI3 kinase in 
ECs leads to the induction of endothelial NOS which produces the potent vasodilator 
nitric oxide. In VSMCs PI3 kinase activation leads to the phosphorylation of MLCK 
which promotes constriction (101; 166). Furthermore, both ECs and VSMCs express ERα 
and ERβ which, when activated, lead to the transcription of a host of proteins associated 
with vascular cell signaling (39). Many of these transcripts confer beneficial phenotypic 
alterations in both ECs and VSMCs resulting in reduced leukocyte adhesion, inhibition of 
VSMC proliferation, and cell survival (38). On the other hand, HT has been associated 
with a genetic variant of the ERβ and it has been clearly documented that E2 taken as an 
oral contraceptive augments blood pressure (27; 93; 149). Additionally, the discontinued 
use of hormone replacement therapy due to increased risk of cardiovascular disease and 
some forms of cancers, shed doubt on the beneficial effects of E2 (9; 82; 98).  
Evidence suggests that male and female animals may utilize different strategies to 
regulate a variety of processes in the body. From cellular mechanisms responsible for cell 
survival (99), to blood pressure regulation by the SNS (57; 62; 138), it appears that 
females may rely on different mechanisms to maintain cardiovascular homeostasis. For 
example, female rats possess NPY and the Y1R, but unlike males, this pathway 
contributes little to baseline blood flow control (74-76). Further, E2 has been shown to 
down-regulate NPY mediated control of hindlimb blood flow in females (77).  
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Moreover, in humans, E2 is the leading candidate behind the so-called ‘female 
advantage’ in cardiovascular disease (80). The ‘female advantage’ refers to the 
epidemiologic observations that prior to menopause, the prevalence and severity of a 
number of cardiovascular diseases, including HT, are markedly lower in females than age 
matched males. Following menopause, the ‘protection’ is lost, and the rates and severity 
of HT and other cardiovascular diseases including atherosclerosis, myocardial infarction 
and coronary artery disease (among others), in women surpass those found in age 
matched males (Figure 1.6). The differences between males and females in figure 1.6 
reflects the prevalence in the population, and while E2 is has been identified as a 
contributor to the dimorphism, little is known about the mechanisms responsible.  
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Figure 1.6 ‒ Prevalence of high blood pressure in adults age 20 and older, by age and 
sex. Rates of hypertension among males are greater than those found in females up until 
45years of age, at which point females surpass males in prevalence. Data from (5). 
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As mentioned, E2 has the ability to both dilate and constrict blood vessels (101; 
166), and can confer both beneficial and adverse effects in systemic vascular regulation 
(27; 38; 93; 149). Further, E2 has also been shown to both augment and reduce vascular 
stiffness which can have direct effects on blood pressure (37; 51; 100; 150). Additionally, 
E2 is known to influence the development of the SNS (6; 28; 182) and can modulate its 
activity (160). Therefore the role of E2 in regulating sympathetic cardiovascular control 
in both health and disease remains unclear.  
1.9 Summary 
Hypertension is a multifactorial condition with much pathology. It manifests 
clinically as augmented arterial pressure and a clear role for the SNS is evident. The role 
of the sympathetic nervous system in established HT has been extensively studied but the 
contribution it plays in the early stages of HT is less well understood. Both the regulation 
of hemodynamics and the mechanical properties of the vasculature are altered in HT. 
This thesis examines the role of NPY in particular, and the SNS in general in regulating 
the changes observed in males and contrasts them with observations made in female 
animals. Furthermore, the ability of the SNS to regulate vascular mechanics in females is 
unknown and the role of the animal’s sex in regulating hemodynamics, vascular 
mechanics and sympathetic control in normotension and HT, will be addressed.  
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Chapter 2 ‒ Enhanced regulation of hindlimb vascular control by 
neuropeptide Y during the development of hypertension 
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2.1 Introduction 
Hypertension (HT) develops early in the life of the spontaneously hypertensive rat 
(SHR; approximately 5-weeks of age). Elevated sympathetic nervous system (SNS) 
activity is often observed in the pathology of hypertension (2; 14; 15; 25) and neonatal 
sympathectomy consistently prevents the development of high blood pressure in the SHR 
(11; 24). Thus, the development of HT is related to sympathetic activation. However, the 
role of specific sympathetic neurotransmitters and post-junctional receptor control in the 
development of HT remains unclear. 
 Sympathetic neurotransmitters responsible for vascular control in skeletal muscle 
include norepinephrine (NE) and neuropeptide Y (NPY). Acutely, these 
neurotransmitters signal vasoconstriction (26) leading to increased peripheral vascular 
resistance. Chronically, these same mediators can exert trophic effects (4), which can 
lead to inappropriate tissue remodeling with outcomes such as wall thickening, wall 
stiffening and lumen narrowing. Of the sympathetic neurotransmitters, NE has received 
most attention as an etiology of HT, and evidence is mounting which suggests a role for 
NPY in vasomotor control (7; 8) and, in particular, HT (5; 16). 
NPY acts via a variety of Y-receptors on vascular smooth muscle cells (VSMC) 
to elicit diverse cardiovascular effects (1; 17). A possible role for NPY in the 
development of HT was shown by Shin et al. (21) who, in a two-kidney, one-clip 
renovascular model of HT, blunted the rise in blood pressure via NPY Y1 receptor (Y1R) 
antagonism, a mechanism that was independent of renin release. Thus, it is possible that 
NPY exerts an important influence on hindlimb vasomotor control in the developing 
stages of HT. The purpose of this experiment was to test the hypothesis that altered 
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neurovascular regulation occurs early in the development of HT with changes that 
include modifications to Y1R and/or α-adrenergic receptor (AR) regulation. Our approach 
was to assess the hindlimb hemodynamic responses of exogenous α-AR and Y1R agonists 
in the early stages of HT and to combine these integrated responses with an analysis of 
receptor protein expression in young hypertensive (SHR) and normotensive (Wistar 
Kyoto; WKY) controls. 
2.2 Methods 
Experimental Animals 
The experimental protocol was approved by the Animal Use Subcommittee at The 
University of Western Ontario. Male Wistar Kyoto (WKY) and spontaneously 
hypertensive (SHR) rats were grouped according to age with emphasis on 3-5 weeks of 
age (SHR, n=10, 108±28 g; WKY, n=11, 89±27 g), 7 weeks of age (SHR, n=16, 199±24 
g; WKY, n=17, 195±6 g) and 9 weeks of age (WKY only, n=5, 260±8 g).  
Data collection and analysis 
Non-invasive blood pressure (NIBP) was measured in a subset of 3-5 (SHR, n=6; 
WKY, n=7) and 7 week-old (SHR, n= 8; WKY, n=8) animals with a volume pressure 
recording sensor and an occlusion tail-cuff (CODA System, Kent Scientific, Torrington, 
CT). Measures of systolic, diastolic, and mean arterial pressures (MAP), as well as heart 
rate (HR) were obtained. The animals were familiarized with the protocol prior to data 
collection. 
All animals underwent an acute in vivo vasomotor control study. Animals were 
anesthetized with an intraperitoneal injection of α-chloralose (80 mg/kg) and urethane 
(500 mg/kg). This mixture was used to ensure minimal impact on reflex cardiovascular 
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control (12; 13). Once surgical depth was achieved, the right jugular vein was cannulated 
with PE50 tubing for the administration of a dilute mixture of α-chloralose (8-16 
mg/kg/hr) and urethane (50-100 mg/kg/hr) to maintain anesthesia throughout the 
protocol. A fluid filled PE50 cannula was inserted into the right common carotid artery to 
record arterial blood pressure using a pressure transducer (model MLT844; 
ADInstruments Colorado Springs, CO) and the signal was amplified using a bridge 
amplifier (model ML118 PowerLab Quad Bridge Amplifier; ADInstruments). HR was 
calculated online from the systolic peaks of the pressure signal and was used in 
conjunction with blood pressure and temperature (rectally) to ensure that the animal 
remained at a stable surgical depth of anaesthesia throughout the experiment. All data 
was collected using Chart 5 (ADInstruments) with a sampling rate of 4000Hz. 
 A midline incision was made to expose the visceral organs which were 
repositioned to reveal the bifurcation of the descending aorta into the iliac arteries. The 
right iliac artery was cannulated with PE50 tubing inserted rostrally to the bifurcation of 
the aorta for the delivery of vasoactive compounds (see below). Femoral blood flow 
(QFem) was measured in the intact (left) hindlimb with a Transonic flow probe (0.7 PSB 
and model TS420 Perivascular Flowmeter Module; Transonic Systems, Ithaca, NY) 
positioned approximately 3mm distal to the femoral triangle. Care was taken to ensure 
that nerves and vessels were not damaged during this process. The area was covered with 
an innocuous water-based gel.  
The animals were allowed to recover from the surgery for 1 hour. Baseline values 
were measured over a 10 minute period after which a 160 μL bolus of the agonists 
phenelypherine (PE; 2.5 µg/kg) or neuropeptide Y (NPY; 15 µg/kg) were administered to 
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all of the animals via the iliac artery. To test the influence of the Y1R in baseline 
cardiovascular control, bolus’ of the selective Y1R antagonist N-[(1R)]-4-
[(Aminoiminomethyl) amino-1-[[[(4-hydroxyphenyl) methyl] amino] carbonyl] butyl-a-
phenylbenzeneacetamide trifluoroacetate (BIBP3226; 100 µg/kg) were infused into the 
hindlimb of a subset of 7-week-old animals (SHR n, = 10; WKY, n = 9). The peak 
response to BIBP3226 was measured approximately 10 minutes following the infusion. 
The ganglionic antagonist hexamethonium bromide (Hex; 25 mg/kg intravenously) was 
infused systemically in all animals to determine the viability of the sympathetic nervous 
system in the preparation. The dose of Hex that was used is higher than that of previously 
published reports (9; 22), in which 20 mg/kg of intravenous Hex abolished (renal) SNA 
in both SHR and WKY animals between 15 and 20 weeks of age. All drugs were 
purchased from Sigma-Aldrich (St. Louis, MO) with the exception of BIBP3226 (Tocris 
Bioscience; Ellisville, MO). 
Changes in femoral vascular conductance (Cond = QFem/MAP x 1000; 
µL/min/mmHg) were used as an indicator of vasomotor contractile state. Drug responses 
were compared using the 5-second average at the nadir and at 360 seconds post infusion, 
and these were compared to a 5-second baseline collected immediately prior to the start 
of the infusion. Additionally, the area over the curve (AOC; arbitrary units, A.U.) was 
calculated using the trapezoid method (20).  
Western blot analysis 
Following the infusion protocol, the red portion of the vastus lateralis muscle 
from the left hindlimb of 7 week-old animals was extracted and frozen for protein 
analysis. Briefly, equal amounts of total protein (60 μg for Y1R and 120 μg for tyrosine 
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hydroxylase (TH) and α-AR) were assessed by western blot. Membranes were incubated 
overnight in primary antibody specific to either rat, human or mouse anti-Y1R (1:300, 
affinity purified rabbit anti-mouse Y1R IgG, Alpha Diagnostic International, Cat. No. 
NPY1R11-A, San Antonio, TX, USA), anti-α1-AR (1:400 affinity isolated rabbit, Sigma-
Aldrich Cat. No. A270) or anti-TH (1:1000 purified rabbit polyclonal antibody, 
Millipore, Cat. No. AB152, Billerica, MA, USA) in TTBS with 2% non-fat milk. 
Membranes were washed 3 times in TTBS then incubated in secondary antibody (goat 
anti-rabbit, or anti-mouse; 1:3000) conjugated to horseradish peroxidase (HRP; Bio-Rad, 
Cat. No. 170-6518) and Precision Protein StrepTactin-HRP Conjugate (1:10000; Bio-
Rad, Cat.No. 161-0380) in TTBS with 2% non-fat milk for 1 hour and developed using 
Immun-Star WesternC chemiluminescent (Bio-Rad, Cat. No. 170-5070) and detected 
using a Bio-Rad ChemiDoc XRS system (Bio-Rad, Cat. No. 170-8070) with a 
supersensitive 16-bit CCD. Images were analyzed using Quantity One 1-D Analysis 
Software (Bio-Rad, Cat. No. 170-9600).  
Statistics 
The effect of age and strain on the progression of hypertension (NIBP measures) 
was assessed with a mixed two-way ANOVA (Statistical Analysis System (SAS) 9.1, 
SAS Institute Inc., Cary, NC, USA). The effects of group and the infused vasoactive 
agonists were assessed by the AOC as well as the difference from baseline at the nadir 
and 360 seconds post infusion using a mixed two-way ANOVA, again, on age and strain. 
The hemodynamic response to BIBP3226 infusion was compared to baseline using a 
paired Student’s t-test within a strain (SigmaStat 3, Systat Software Inc., San Jose, 
California, USA). Western blot data were compared between strains of the 7 week-old 
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animals using an equal variance Student’s t-test (SigmaStat 3). Differences were 
considered significant at P<0.05 and Tukey’s post hoc analysis was used to identify 
where differences occurred in the ANOVAs. Data are represented as mean ± standard 
deviation. 
2.3 Results 
Non-invasive blood pressure 
As expected, SHRs had higher arterial pressure as measured by NIBP versus 
WKYs (Table 2.1). Additionally, 7 week-old animals (of both strains) had higher 
pressure than 3-5 week-olds. Anesthetic administration dropped blood pressure, however, 
data from our lab indicates that reflex cardiovascular control using this anesthetic is 
maintained (Usselman et al., In Press)  
In Vivo vasomotor control study 
Hemodynamic values during baseline and following Hex administration can be 
found in Table 2.1. Table 2.2 depicts the hemodynamics following bolus infusions of 
both PE and NPY. Figure 2.2 shows the change in Cond in response to PE in 3-5 week 
and 7 week-old SHR and WKY animals (Figure 2.2; top and bottom respectively). In 
response to PE infusion, Cond in 3-5 week-old WKY animals fell by 2.8±2.9 
µL/min/mmHg (P<0.05 versus baseline) and returned to baseline by 360s (not significant 
(N.S.) versus baseline). The femoral vascular conductance of 3-5 week-old SHR animals 
fell by 2.9±2.8 µL/min/mmHg (P<0.05 versus baseline) in response to PE and returned 
to baseline at 360s (N.S. versus baseline). In 7 week-old WKY animals, PE did not 
significantly reduce Cond (N.S.) but in 7 week-old SHR animals Cond fell by 8.1±6.3 
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µL/min/mmHg (P<0.05 versus baseline) and remained depressed past 360s (4.7±3.4 
µL/min/mmHg; P<0.05 versus baseline).  
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Figure 2.1 ‒ Representative raw data tracings from 7 week old spontaneously 
hypertensive (SHR) and Wistar-Kyoto (WKY) rats in response to both neuropeptide Y 
(NPY; 15μg/kg) and phenylephrine (PE; 2.5μg/kg). Solid line represents the start of drug 
infusion (0 seconds) and dashed line represents 360 seconds post infusion. 
 
 
Table 2.1 ‒ Non-invasive blood pressure and in vivo hemodynamic variables at baseline and following ganglionic blockade. 
  NIBP  Anesthetized Baseline  Hexamethonium (25mg/kg) 
Strain 
Age 
Group 
 
MAP 
(mmHg) 
 
MAP 
(mmHg)
HR 
(BPM) 
QFem 
(mL/min) 
Cond 
(µL/min/mmHg) 
 
MAP 
(mmHg)
HR 
(BPM) 
QFem 
(mL/min) 
Cond 
(µL/min/mmHg) 
WKY 
3-5  102±21  68±12 391±52 0.49±0.35 7.5±6.2  59±6* 355±25 0.80±0.18* 13.6±2.8* 
7  128±19‡  72±13 314±73 0.69±0.35 9.9±5.6  67±2 348±51 0.91±0.37* 13.7±5.6*‡ 
9  --  73±11 300±30‡ 0.57±0.32 7.5±3.4  61±4* 365±22* 0.69±0.19 11.2±2.9 
SHR 
3-5  141±20†  89±19† 462±28† 0.57±0.42 6.7±4.7  64±9* 405±24† 0.70±0.15* 11.2±3.2* 
7  157±22†  94±21† 377±59‡† 0.97±0.64† 10.2±5.4  79±5*† 372±15‡ 1.06±0.44‡ 14.1±6.3† 
Values are mean ± standard deviation. Spontaneously hypertensive rat = SHR; Wistar-Kyoto = WKY; non-invasive blood pressure = 
NIBP; mean arterial pressure = MAP, heart rate = HR, femoral blood flow = QFem and femoral vascular conductance = Cond. * 
denotes P<0.05 versus baseline; † denotes P<0.05 versus age-matched WKY; ‡ denotes P<0.05 versus 3-5 week-old within the same 
strain.
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Table 2.2 – Hemodynamic response prior to and following phenylephrine and 
neuropeptide Y. 
Strain Age (Weeks)
MAP 
(mmHg)
HR 
(BPM) 
QFem 
(mL/min) 
Baseline (Prior to Drug Infusion) 
SHR(n=10) 3-5 85±17* 460±14* 0.50±0.34 
WKY(n=11) 3-5 71±13 369±30 0.47±0.37 
SHR(n=8) 7 97±11* 453±8* 1.32±0.51* 
WKY(n=8) 7 80±18 351±46 0.68±0.56 
PE
SHR 3-5 98±18
a 455±16* 0.29±0.22a 
WKY 3-5 90±16
a 366±22 0.33±0.33a 
SHR 7 110±8a 448±8* 0.52±0.12a 
WKY 7 99±22a 363±57 0.43±0.49a 
NPY
SHR 3-5 104±16
a 452±15* 0.33±0.38a 
WKY 3-5 95±18
a 368±25 0.31±0.26a 
SHR 7 120±14a 457±16* 0.34±0.25a 
WKY 7 109±10a 332±13 0.45±0.55a 
 
Values are mean ± standard deviation. Spontaneously hypertensive rat = SHR; Wistar-
Kyoto = WKY; mean arterial pressure = MAP, heart rate = HR and femoral blood flow = 
QFem; PE = phenylephrine (2.5μg/kg); NPY = neuropeptide Y (15μg/kg). * denotes 
P<0.05 versus baseline (of same age group). Main effect statistics: a denotes P<0.05 
versus baseline.  
 
58 
 
 
 
Figure 2.2 – The change in hindlimb conductance to phenylephrine (PE; 2.5μg/kg) in 3-5 
week-old (top) and 7 week-old (bottom) spontaneously hypertensive (SHR) and Wistar 
Kyoto (WKY) rats. Nadir represents the minimum conductance reached and 360 
represents 360 seconds post infusion. Values are mean ± standard deviation. * denotes 
P<0.05 versus baseline. Refer to Table 2.1 for baseline values. 
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Figure 2.3 depicts change in Cond in responses to NPY in both 3-5 and 7 week-
old SHR and WKY animals (Figure 2.3; top and bottom respectively). In 3-5 week-old 
WKY animals, NPY reduced Cond by 4.0±4.1 µL/min/mmHg (P<0.05 versus baseline) 
which returned to baseline by 360s (N.S.). With NPY infusion, femoral vascular 
conductance fell in the 3-5 week-old SHR animals by 2.5±2.3 µL/min/mmHg (P<0.05 
versus baseline) and returned to baseline by 360s (N.S.). In 7 week-old WKY animals, 
Cond was not significantly reduced (N.S. versus baseline), but fell by 5.9±3.4 
µL/min/mmHg (P<0.05 versus baseline) in 7 week-old SHR animals and remained 
depressed at 360s (2.8±2.7 µL/min/mmHg; P<0.05 versus baseline). 
 The areas over the curve (AOC) for both NPY and NE in SHR and WKY animals 
were not different between either strain or drug at 3-5 week of age (Figure 2.4; top, N.S.). 
At 7 weeks of age, the AOC in response to PE was not different between the strains; 
however, the response to NPY was greater in SHR animals versus WKY animals (Figure 
2.4; bottom; P<0.05 versus WKY in NPY).  
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Figure 2.3 ‒ The change in femoral vascular conductance to neuropeptide Y (NPY; 15 
μg/kg) in 3-5 week-old (top) and 7 week-old (bottom) spontaneously hypertensive (SHR) 
and Wistar Kyoto (WKY) rats. Nadir represents the minimum conductance reached and 
360 represents 360 seconds post infusion. Values are mean ± standard deviation. * 
denotes P<0.05 versus baseline. Refer to Table 2.1 for baseline values. 
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Figure 2.4 ‒ Area over the curve (AOC) of femoral vascular conductance in response to 
phenylephrine (PE; 2.5 μg/kg) and neuropeptide Y (NPY; 15 μg/kg) in spontaneously 
hypertensive (SHR) and Wistar Kyoto (WKY) rats. Values are mean ± standard 
deviation. * denotes P<0.05 versus WKY. 
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Figure 2.5 ‒ Representative raw data tracing from 7 week old spontaneously 
hypertensive (SHR) and Wistar-Kyoto (WKY) rats in response to BIBP3226 infusion. 
BIBP3226 data were taken approximately 10 minutes post infusion. Bar represents 50 
seconds.  
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Figure 2.6 – Femoral vascular conductance in 7 week-old spontaneously hypertensive 
(SHR) and Wistar-Kyoto (WKY) rats at baseline and following BIBP3226 (100µg/kg). 
Peak response occurred approximately 10 minutes after infusion. Values are mean ± 
standard deviation. * depicts P<0.05 versus SHR baseline.  
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 In the 7 week-old WKY animals, hindlimb conductance was 9.6±3.9 at baseline 
and 12.0±4.4 µL/min/mmHg (N.S. versus baseline) following BIBP3226 infusion. 
However, Cond in the 7 week-old SHR animals increased from 9.4±4.3 µL/min/mmHg at 
baseline to 15.5±6.5 µL/min/mmHg following BIBP3226 (P<0.05 versus baseline; 
Figure 2.6). 
 Following Hex administration, the hemodynamic responses in the 3-5 week-old 
group from both strains were similar whereby MAP decreased, HR decreased and Cond 
increased (Table 2.1). However, divergent responses were observed between the SHR 
and WKY animals at 7 weeks of age in response to Hex. Most notably, MAP was 
reduced in the SHR animals, while no changes were observed in 7 week-old WKY 
animals. It is noted here that the fall in MAP with Hex in the SHR group was not 
accompanied by a rise in heart rate which stands in contrast to the WKY group which 
experienced tachycardia. This observation raised the question as to whether the divergent 
responses between strains at 7 weeks were due to animal maturation and not hypertension 
per se. To address this question, the Hex approach was repeated in a subset of 9 week-old 
WKY animals. In this group ganglionic blockade evoked reductions in MAP and a rise in 
HR following Hex (Table 2.1). These responses were closer to those of the 7 week-old 
SHR animals than 7 week-old WKY animals.  
Western Blot Analysis 
Distinct bands of chemiluminescence were observed for the Y1R, α-AR and TH. 
The Y1R expression in SHR red vastus was 1.7±0.5 A.U. compared to 1.2±0.6 A.U. in 
the WKY animals (P<0.05; Figure 2.7, top). There were no differences between the 
strains in either α-AR (Figure 2.7, middle) or TH expression (Figure 2.7, bottom). 
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Figure 2.7 ‒ Western blot analysis of the neuropeptide Y (NPY) Y1 Receptor (Y1R; top), 
α-adrenergic receptor (α-AR; middle) and tyrosine hydroxylase (TH; bottom) in the red 
portion of the vastus lateralis from spontaneously hypertensive (SHR; black bar) and 
Wistar-Kyoto (WKY; grey bar) rats. Insert in box - representative western blot for each 
protein. Values are mean ± standard deviation.* denotes P<0.05 versus WKY. 
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2.4 Discussion 
 The main finding of the present study is that following a bolus of NPY, but not 
PE, 7 week-old SHR animals exhibited greater and prolonged reductions in Cond 
compared to age-matched WKY animals. Additionally, 7 week-old SHR animals 
displayed a greater dilatory response to Y1R antagonism with BIBP3226 versus WKY 
animals, and the expression of the Y1R in skeletal muscle was greater in SHR versus 
WKY rats. These data suggest that the involvement of the NPY system in cardiovascular 
regulation is upregulated in the early stages of hypertension.  
 The currently accepted role of the SNS in hypertension is heightened sympathetic 
activity leading to increased vascular resistance (3; 10). While it is traditionally thought 
that norepinephrine and the α-AR are primarily responsible for these effects (6; 23), the 
current data highlight an augmented role for the NPY system in the early stages of the 
condition. The divergent responses observed between the strains to the exogenous 
agonists (PE and NPY) only emerged at 7 weeks of age. The lack of differentiation 
between the strains to either PE or NPY at 3-5 weeks of age indicates that there appears 
to be a temporal onset of modified neurovascular coupling. In this context, it appears that 
the NPY system develops earlier in SHR animals than in the WKY strain.  
Regulation of the NPY system could be altered in a number of ways: 1) enhanced 
NPY bioavailability following either increased neurotransmitter release and/or reduced 
neurovascular proteolytic breakdown, 2) modified Y1R expression, and/or 3) altered post-
receptor regulation of receptor sensitivity or intracellular contractile machinery. Here we 
examined the second option with emphasis on adrenergic and NPY-mediated 
neurovascular regulation. SHR and WKY animals displayed similar reductions in Cond 
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to exogenous PE and showed no difference in the expression of TH, the rate limiting 
enzyme in the production of norepinephrine, or in the α-AR expression, the primary 
receptor governing the VSMC response to norepinephrine. Therefore, we conclude that 
the adrenergic system is not modified between SHR and WKY animals at 7 weeks of age. 
In contrast, the increased expression of Y1R in skeletal muscle observed in the SHR 
coincided with the heightened or prolonged in vivo responses to Y1R activation or 
blockade. These data indicate that the NPY system of 7 week-old SHR animals plays a 
larger role in sympathetic control of hindlimb vasculature compared to age matched 
WKYs. 
The main purpose of the Hex condition was to determine if ganglionic control 
over the cardiovascular system was maintained under anaesthesia. To this end, the current 
Hex results indicate that residual autonomic control was present whereby ganglionic 
blockade produced a reduction in blood pressure in both strains. This hypotensive 
response tended to be greater in the SHR (-28 and -16% change from baseline in 3-5 and 
7 week old SHRs respectively) than WKY (-14, -6 and -16% change from baseline in 3-
5, 7 and 9 week old WKYs respectively) suggesting a greater role for autonomic 
cardiovascular regulation in hypertensive animals. This is consistent with previous 
reports (2) of elevated sympathetic activation in SHR. The new observation of this study 
was that these differences are evident as early as 7 weeks of age. 
However, an unexpected observation of the current study was the age-associated 
difference in the response to ganglionic blockade. While determining the mechanistic 
detail of neurovascular control in developing HT was not the purpose of the Hex trials, 
the observations deserve consideration. In both strains at 3-5 weeks of age, Hex caused 
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reductions in MAP and HR. The bradycardia and Hex-induced hypotension suggest 
immature reflexive cardiac control in 3-5 week-old animals. This pattern was modified 
by 7 weeks of age. The 7 week-old WKY animals demonstrated a smaller hypotensive 
response to Hex which was accompanied by the expected tachycardia, both of which 
were augmented to statistically significant levels by 9 weeks of age. In contrast, the SHR 
animals failed to mount a tachycardic response to Hex despite a marked fall in blood 
pressure. To examine whether the altered response to Hex by 7 weeks in SHR versus 
WKY animals was simply due to a more rapid maturation of neurovascular coupling in 
the SHR strain, a separate group of 9 week-old WKY animals was studied to see if they 
would mimic the 7 week-old SHR group. In this group, Hex induced a marked fall in 
MAP with the expected increase in HR. Thus, there appears to be important age-
dependent alterations in neurovascular coupling in both strains, with the potential for 
aberrant development in the SHR strain that contributes to hypertension. 
The augmented hindlimb vascular conductance to BIBP3226 infusion suggests 
the intriguing possibility that the heightened Y1R regulation in 7 week old SHR animals 
may contribute to the early stages of HT. This observation is counter to reports from Y1-
receptor knockout mice (18) or from studies reporting an acute infusion of BIBP3226 
does not affect basal blood pressure in normotensive or SHR rats (27). However these 
reports were conducted in older animals, and the response here may be specific to the 
initial stages of HT. Nonetheless, chronic activation of the Y1R, independent of changes 
in blood pressure, is mitogenic resulting in vascular wall thickening and stiffening (19) 
which would have a concurrent impact on basal blood pressure and its long-term 
regulation.  
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2.5 Conclusion 
 The prolonged reduction in femoral vascular conductance observed in response to 
exogenous infusions of NPY in SHR but not WKY support the hypothesis that altered 
neurovascular regulation occurs in HT. Specifically, SHR animals appear to emphasize 
enhanced Y1R regulation of hindlimb vascular conductance versus WKY animals. These 
in vivo observations were supported by an increased expression of Y1R in skeletal muscle 
extracts from SHR while α-AR content was similar to WKY control animals.  
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Chapter 3 ‒ Y1 Receptor versus sympathetic control of hindlimb 
vascular stiffness in spontaneously hypertensive rats. 
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3.1 Introduction 
Chapter 2 examined the reaction of the vasculature to the sympathetic agonist’s 
phenylephrine (PE) and neuropeptide Y (NPY). The vasculature of young spontaneously 
hypertensive rats (SHR) was more responsive to exogenously administered NPY versus 
the α-adrenergic receptor agonist PE when compared with normotensive Wistar-Kyoto 
rats (WKY). These differences were associated with an increased expression of the NPY 
Y1 receptor (Y1R) in SHR animals versus WKYs, while markers of adrenergic signaling 
(i.e. α-adrenergic receptor and tyrosine hydroxylase) were unchanged between the strains. 
Thus, it was concluded that enhanced Y1R activation may influence the development of 
HT in the SHR animal. 
Infusing an agonist can expose differences between strains in the responsiveness 
of the vasculature to a stimulus through alterations in receptor activation, signal 
transduction and/or second messenger signaling. However, this approach provides no 
information on the role of that receptor system on baseline or chronic receptor activation. 
Alternatively, by antagonizing a receptor, one can prevent signal transduction into the 
cell and uncover the role that a specific system (i.e. NPY and the Y1R) plays in both 
normal and abnormal conditions. Whereas much emphasis has been placed on 
norepinephrine as the major sympathetic neurotransmitter affecting the development of 
HT, a growing body of evidence suggests that NPY plays an important role in HT (17; 
23; 28; 29). The attention given to NPY is due, in part, to its physiologic actions which 
include potent and long-lasting vasoconstriction (27), potentiation of norepinephrine 
induced contraction (10), and mitogenesis (1). Each of these actions parallel a 
characteristic of established HT (25).  
 
75 
 
In 1989, Adams and colleagues (2) reported changes in perfusion pressure across 
a range of flow rates that suggested hindlimb vascular remodeling had occurred as early 
as 4-6 weeks of age in the SHR; vascular changes that may have even preceded the rise in 
blood pressure. This functional evidence of vascular remodeling occurred in concert with 
elevated tissue norepinephrine supporting the hypothesis that sympathetic hyperactivity 
early in the lifespan of SHR animals is an important contributor to the remodeling 
process (2; 16). The mechanism governing this sympathetic hyperactivity in HT is not 
clear but probably involves the potentiating impact of sympathetic neurotransmitters on 
local vascular growth factors (2; 6). It is notable that vascular remodeling will affect not 
only the long-term regulation of blood pressure but also the acute responsiveness of a 
vascular bed to neural inputs (22). 
 Evidence to date has emphasized the role of vascular resistance and the narrowing 
of blood vessels as a primary long-term determinant of HT (8; 9; 18). In addition, 
vascular stiffness is an important contributor to blood pressure and cardiac work as stiffer 
vessels transmit pressure waveforms to and from peripheral reflection points faster than 
normal. This causes the reflected pressure waveforms to return to the aorta during 
systole, therefore increasing systolic pressure and cardiac work, as opposed to diastole 
which actually aides in coronary perfusion (19; 20). Moreover, the role of the heightened 
sympathetic outflow on the stiffness and/or resistance of the intact hindlimb vascular bed 
in the early stages of HT have not been studied.  
Therefore, the purpose of this study was to explore the acute roles of both the Y1R 
in particular, and the sympathetic nervous system (SNS) in general, in regulating the 
mechanical properties of the rat hindlimb and how each might be modified by HT. We 
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tested the specific hypothesis that Y1R activation contributed to vascular stiffness in the 
developmental stages of HT in the SHR model. Furthermore, we also tested the more 
general hypothesis that sympathetic activation per se (regardless of the neurotransmitters 
involved) affected vascular stiffness and viscoelasticity in the SHR hindlimb. 
3.2 Methods 
Experimental Animals 
 The following protocol was approved by the Animal Use-Subcommittee at The 
University of Western Ontario. Seven week old male Wistar-Kyoto (WKY; 207±16g, n = 
7) and spontaneously hypertensive (SHR; 214±15g, n=10) rats were used in this 
experiment. Rats were housed in a light (12 h cycle) and temperature (22°C) controlled 
room in Plexiglas cages. Rats were allowed to eat (Prolab Rat chow, Mouse and Hamster 
3000 Diet) and drink water ad libitum. 
Data collection 
All animals underwent an acute in vivo vasomotor control study. Animals were 
anesthetized with an intraperitoneal injection of α-chloralose (80 mg/kg) and urethane 
(500 mg/kg). The mixture of urethane and α-chloralose was used to minimize the impact 
of anesthetic on reflex cardiovascular control (14; 15). At a surgical depth of anesthesia, 
the right jugular vein was cannulated (PE50 tubing) so as to administer a dilute mixture 
of α-chloralose (8-16 mg/kg/hr) and urethane (50-100 mg/kg/hr). Mean arterial pressure 
(MAP; mmHg) was measured in the right common carotid artery using a fluid filled 
cannula (PE50 tubing) connected to a pressure transducer (model MLT844; 
ADInstruments Colorado Springs, CO) and bridge amplifier (model ML118 PowerLab 
Quad Bridge Amplifier; ADInstruments). Heart rate (HR; beats/min) was calculated 
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online using R-R peaks from sub-dermal ECG electrodes (model FD-E2; Grass 
Technologies West Warwick, RI) and a vital signs monitor (model 78353B; Hewlett 
Packard Palo Alto, CA) was used in conjunction with blood pressure and temperature 
(rectally) to ensure that the animal remained at a stable surgical depth of anaesthesia 
throughout the experiment. 
The visceral organs were exposed via a midline incision in the abdomen. The 
right iliac artery was cannulated (PE50 tubing) to measure blood pressure at the level of 
the bifurcation of the aorta. Aortic blood flow (QAorta) was measured just superior to the 
bifurcation of the aorta using a flowmeter (model TS420 Perivascular Flowmeter Module; 
Transonic Systems, Ithaca, NY) and Transonic flow probe (2.5 PSB). Pulse wave velocity 
(PWV; cm/s) was measured as described by Cosson et al. (4). Briefly, the time difference 
(T; seconds) between the diastolic foot of the pressure waveform at the carotid (proximal) 
and iliac (distal) arteries were measured. The distance (D; cm) between the catheter tips 
was measured post mortem, and PWV was calculated as (D/T; cm/s).  
Baseline values were measured during a 10 minute period. To test the influence of 
the Y1R in baseline cardiovascular control and vascular stiffness, a bolus of the selective 
Y1R antagonist N-[(1R)]-4-[(Aminoiminomethyl) amino-1-[[[(4-hydroxyphenyl) methyl] 
amino] carbonyl] butyl-a-phenylbenzeneacetamide trifluoroacetate (BIBP3226; 100 
µg/kg) was infused into the hindlimb. The peak response to BIBP3226 was measured 
approximately 10 minutes following the infusion. Once baseline values were re-
established the neuronal nicotinic acetylcholine receptor agonist hexamethonium bromide 
(Hex; 25 mg/kg, Sigma-Aldrich, St. Louis, MO) was introduced systemically to abolish 
post-ganglionic nerve activity. Once a new hemodynamic baseline was achieved, 10 
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minutes of data were recorded. All drugs were purchased from Sigma-Aldrich (St. Louis, 
MO) with the exception of BIBP3226 (Tocris Bioscience; Ellisville, MO). 
Data Analysis 
MAP (mmHg), HR (beats/min), QAorta (mL/min), PWV (cm/s), and compliance of 
the distal aorta (CLocal = [ΔQxΔT]/ΔP; mL/mmHg, Figure 3.1) were calculated. CLocal is a 
surrogate of the local compliance at the level of the distal aorta. The traditional method 
for assessing cardiovascular regulation is by examining changes in vascular resistance (R) 
which, fundamentally, reflects a steady-state level of vascular diameter. Thus, by itself, R 
relates information regarding the steady component of blood flow alone (13; 21). Since 
blood flow is pulsatile, it incorporates both steady state and oscillatory blood flow (19). 
In contrast with R, the stiffness of a vessel, or vascular bed, is related to the oscillatory 
nature of blood flow in distensible vessels. In a pulsatile system, it is necessary to 
examine the impedance which reflects the frequency-specific resistance and is expressed 
in the compliance (C) and viscoelasticity (K) of the vessel wall, and the inertia (L) of 
blood and vessel tissue (30). Thus, the vascular resistance (R) and mechanical properties 
(C, K and L) of the hindlimb vascular bed were estimated using the aortic flow and 
pressure waveforms measured at the distal end of the aorta using a modified Windkessel 
model (30; 31). Briefly, the model modifies the values of C, K and L to predict a flow 
waveform that would be produced from the measured pressure waveform. The predicted 
waveform is then compared iteratively with the measured flow waveform until the best 
agreement is achieved, providing the values of C, K and L.  
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Figure 3.1 – Calculation of local aortic compliance (CLocal). Beat-by-beat averages of 10 
consecutive distal aortic pressure (P, top) and flow (Q, bottom) waveforms were 
averaged. CLocal was calculated as the change in flow (ΔQ; mL/min) multiplied by the 
time to peak flow (ΔT; min) divided by the pulse pressure (ΔP; mmHg). Thus, CLocal = 
[ΔQxΔT]/ΔP; mL/mmHg.  
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Statistics 
The effects of rat strain (SHR/WKY) and drug (baseline/BIBP3226/Hex) were 
compared using a mixed two way analysis of variance (ANOVA; SAS 9.1, Cary, NC, 
USA). Statistical significance was accepted at P<0.05. Tukey’s post hoc analysis was 
used to identify differences in main effects and interactions. All data are expressed as 
mean ± standard deviation.  
3.3 Results 
Hemodynamics 
SHR animals had higher MAP compared to WKYs (Figure 3.2 I; main effect of 
strain, P<0.05). BIBP3226 had no effect on MAP in either strain; however following 
Hex, MAP fell (main effect of drug, P<0.05 versus baseline and BIBP3226). QAorta was 
higher in the WKY animals (data not shown; main effect of strain, P<0.05) and neither 
BIBP3226 nor Hex had any effect on QAorta. Vascular resistance (R = MAP/QAorta) was 
greater in SHRs compared to the WKYs at baseline and during BIBP3226, but not during 
Hex infusion (Figure 3.2 II; strain x drug interaction, P<0.05). BIBP3226 infusion had no 
effect on R in either strain, but following Hex R fell in the SHRs only (P<0.05 versus 
baseline and BIBP3226 in SHR only). 
Systemic Vascular Stiffness 
At baseline, PWV was greater in the SHRs compared to the WKYs (Figure 3.2 
III; main effect of strain, P<0.05). Compared with baseline, PWV was unaltered 
following BIBP3226 infusion but was decreased following Hex in both strains (main 
effect of drug, P<0.05 versus baseline and BIBP3226). 
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Figure 3.2 ‒ Mean arterial pressure (MAP; I), caudal aortic vascular resistance (R; II) 
and pulse wave velocity (PWV; III) from young hypertensive (SHR) and normotensive 
(WKY) rats. Values are mean ± standard deviation. *, significantly different from 
baseline (within a strain); €, significantly different from BIBP3226 (within a strain); †, 
significantly different from WKY baseline; ‡, significantly different from WKY 
BIBP3226. Main effect statistics ‒ a, significantly from baseline; b, significantly different 
from BIBP3226; c, significantly different from WKY. All statistics P<0.05 
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Hindlimb Vascular Mechanics 
When compared with WKY, C and CLocal were lower in SHR (Figure 3.3 I and II 
respectively; main effect of strain, P<0.05). BIBP3226 infusion had no effect on 
hindlimb vascular compliance in either strain (N.S. versus baseline) but both C and CLocal 
were increased in both strains following Hex (main effect of drug, P<0.05 versus both 
baseline and BIBP3226). K was greater in SHRs compared with WKYs (Figure 3.3 III; 
main effect of strain, P<0.05) and K was reduced in both strains following Hex only 
(main effect of drug, P<0.05 versus baseline and BIBP3226). 
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Figure 3.3 ‒ Hindlimb vascular bed compliance (C; I), local aortic compliance (CLocal; II) 
and viscoelasticity (K, III) of the lumped hindlimb vascular beds of young hypertensive 
(SHR) and normotensive (WKY) rats. Values are mean ± standard deviation. Main effect 
statistics ‒ a, significantly from baseline; b, significantly different from BIBP3226; c, 
significantly different from WKY. All statistics P<0.05 
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3.4 Discussion 
 The purpose of this study was to assess the role of the NPY Y1R specifically, and 
the SNS generally, in regulating the mechanical properties of the rat hindlimb, and 
whether this regulation is modified in the early stages of HT. In particular, emphasis was 
placed on the impact of Y1R under baseline conditions. As expected, vascular stiffness 
and resistance were greater in the SHR versus WKY animals. These differences were 
present regardless of whether the measurements were made locally (e.g., C or CLocal in the 
hindlimb) or systemically (e.g., PWV). Contrary to our specific hypothesis the NPY Y1R 
has little regulatory control of hindlimb vascular mechanics during developing HT. 
Therefore, the SNS does exert some control over the hemodynamic and mechanical 
properties of the rat hindlimb, which are presumably mediated by adrenergic and/or 
purinergic mechanisms. 
Vascular Resistance 
Changes in R have been used to reflect vasomotor contractile state and 
sympathetic neurovascular control in cardiovascular research for many years (12). 
Enhanced SNS activity is routinely seen in HT, and it is suspected that increased R 
accounts for some of the augmented pressure (3; 5). This study confirms that the SNS is 
responsible for the increased R seen in HT at 7 weeks of age. R was unaffected by Hex in 
the normotensive WKY animals which is surprising considering other groups have 
reported Hex induced falls in regional vascular resistances in a variety of vascular beds in 
WKYs (26). These regional reductions in R were measured in conscious unrestrained 
animals therefore; the effect of anaesthesia in reflex cardiovascular control must be 
addressed. Data from our lab indicates that the urethane/α-chloralose cocktail used here 
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does not impair autonomic reflexes in response to lower body negative pressure 
(Usselman et al., In Press). Thus, R in the WKYs appears to be independent of 
sympathetic activity at 7 weeks of age. 
Vascular Stiffness 
A hallmark of HT is vascular stiffening which leads to faster pressure wave 
reflections and increased afterload on the left ventricle (20). Here, we have shown that 
such stiffening occurs early in the development of HT, namely, in 7-week old SHR 
animals, and this stiffening is not restricted to a particular region or level of the vascular 
tree but appears to be a generalized feature of SHR at 7 weeks of age. Moreover, changes 
in C, CLocal, PWV and K were observed in WKY animals following Hex, without a 
change in R. Therefore, the mechanics of the vasculature can be studied independently 
from vascular resistance, supporting earlier observations from our lab (30).  
Y1R antagonism resulted in little change in PWV, CLocal or hindlimb C in either 
strain. Therefore, the current results do not support the hypothesis that Y1R activation is, 
by itself, an important contributor to vascular stiffening in SHR. However, ganglionic 
blockade did affect hindlimb vascular properties. Nonetheless, an important unresolved 
question in the study of the developing of HT is whether the observed stiffening of the 
vasculature is due to chronic remodeling or to more acute changes in sympathetic 
activation. One interpretation of the current results is that baseline levels of SNS 
activation contribute to vascular stiffness in both SHRs and WKYs. However, it is noted 
that, following Hex, C and CLocal increased whereas PWV and K fell with a concomitant 
fall in MAP. Therefore, the involvement of myogenic contributions to these variables 
cannot be ruled out. Additionally, changes in C may reflect the compliance of the 
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vascular bed at a different point on the same pressure-volume curve. As such, the changes 
in compliance observed may not indicate an actual shift in the mechanical properties of 
the vasculature.  
Viscoelasticity 
To our knowledge, this is the first attempt to examine the impact of sympathetic 
control on the viscoelastic properties of the vasculature and how it is affected by HT. The 
first observation was that K was much greater in SHR animals compared with WKY 
controls at baseline. Thus, viscoelastic resistance to vascular distension is greater in SHR 
and could contribute to augmented blood pressure. Second, K was unaffected by Y1R 
antagonism but was lower following ganglionic blockade in both strains. Thus, the 
augmented K in young SHR appears to be due primarily to neural regulation and not 
chronic changes in the vascular wall matrix as would be predicted by vascular 
remodeling. In other words, it is the contractile component of the vascular bed that is 
causing the elevated value of K in SHR. Thus, the neurogenic regulation of K may be 
treated as an abnormality associated with the HT. This supposition awaits further 
experimentation as altered vascular wall structure may also affect its contractile 
properties (22).  
Limitations 
A major limitation to this study is the absence of measured sympathetic nerve 
activity. Thus, it is assumed that sympathetic outflow was elevated in the SHR animals, 
an assumption that has been validated previously (see (7) for a detailed review).  
Using a chemical agent to antagonize ganglionic neural transmission, we can 
reasonably assume that complete ganglionic blockade occurred with Hex as previously 
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published reports (11; 24) indicate that 20mg/kg was a sufficient dose to completely 
block post-ganglionic neural transmission as measured in the renal nerve in both SHR 
and WKY animals.  
3.5 Conclusion 
 The current results suggest that the increased vascular resistance in 7-week old 
SHR animals is neurally mediated, but does not involve the NPY Y1R. Markers of 
vascular stiffness (C, CLocal, K, and PWV) displayed some neural control in both strains, 
but again, the Y1R did not participate. Thus, it appears that neural activation contributes 
to baseline vascular stiffening and resistance in early stages of hypertension. However, 
this neural involvement does not include Y1R activation. Nonetheless, levels of hindlimb 
R in 7-week old WKY animals appear to be independent of neural activation. These 
observations contrast with the prolonged Y1R activation in young SHR in response to 
agonist infusion and highlight the importance of non-NPY sympathetic neurotransmitters 
in chronic vasomotor control in young SHR. Therefore, the current results suggest that 
increased vascular stiffness is evident early in HT, and this stiffening appears to be under 
neural control.  
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Chapter 4 ‒ Sympathetic Contribution to Peripheral Vascular Stiffness 
in Young Female Spontaneously Hypertensive Rats. 
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4.1 Introduction 
The etiology of essential hypertension (HT) is complex and includes both a 
sustained increase in sympathetic nervous system (SNS) activity (4; 10; 22; 34; 44) that 
begins early in life (3; 8; 38), and a remodeled vascular bed (25). Evidence is growing 
which indicates that male and female animals differ in a number of physiological 
parameters (12; 13; 24; 26; 35), but the reason for these differences remains unknown. 
This chapter explores the mechanical properties of the vasculature during development of 
HT in young female animals. As figure 1.6 indicates, the prevalence of HT in humans 
displays sexual dimorphism. These differences are evident in the youngest age bracket 
(20-34 years) which indicates that the processes responsible are present throughout life, 
but appear to change with age (1). Unlike chapters 2 and 3, this chapter does not include 
agonist or antagonist interventions, but focuses solely on hemodynamic and mechanical 
properties of the vasculature at baseline and following the administration of 
hexamethonium bromide. Agonist stimulation was not included in the analysis because 
stable hindlimb blood flow values were unattainable in young female animals (See 
Appendix A.1). Also, antagonism of the neuropeptide Y (NPY) Y1 receptor (Y1R) was 
not performed, because, the NPY and Y1R system contributes little to baseline blood flow 
control in female rats (13-15), and also because chapter 3 suggests that the Y1R does not 
regulate the mechanical properties of the vasculature.  
It is generally accepted that enhanced SNS activity and vascular remodeling, 
combine to enhance blood pressure through changes in vascular resistance (R) and 
stiffness (2; 6; 27; 32) (Figure 4.1). However, R reflects vascular resistance to only the 
steady component of blood flow (17; 31) and, therefore, has limited diagnostic function 
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in the context of the oscillatory component of blood flow (29). To better understand the 
mechanisms responsible for controlling pulsatile (steady plus oscillatory) blood flow, it is 
necessary to consider the impedance rather than R (40). The impedance in pulsatile blood 
flow involves R, but also the compliance (C) and viscoelasticity (K) of the vessel wall, 
and the inertia (L) of blood and vessel tissue (41). These properties are involved in the 
regulation of blood flow, yet the role that the SNS plays in regulating C and K has yet to 
be elucidated (Figure 4.1). Previously, it was shown that the brachial artery (33) and the 
forearm vascular beds (41) of humans stiffen during reflex maneuvers that elevate 
sympathetic outflow. The particular impact of sympathetic neural control of vascular 
mechanics was not assessed in these earlier studies. Thus, the neurogenic regulation of 
vascular mechanics is not known in either central or peripheral vascular beds, particularly 
in the context of developing HT. Also, little is known about the role of vascular 
remodeling in modifying neurogenic vasomotor control. Vascular remodeling is typically 
manifest as vascular smooth muscle hypertrophy (11), leading to wall thickening and 
increased arterial stiffness. In common practice, vascular stiffness is determined by 
measuring pulse wave velocity (PWV) along an arterial segment (9; 21) and is then used 
as a global measure of vasular stiffness. In this process, the measure of PWV does little 
to determine whether the stiffness is located centrally or peripherally, or what the root 
cause of the stiffness is in terms of mechanical properties of the vessel wall that affect its 
stiffness.  
Hypertension develops early in the life of spontaneously hypertensive rats (SHR; 
approximately 5-weeks of age) where an elevated sympathetic outflow is often observed 
(23). Also, neonatal sympathectomy is known to consistently prevent the development of 
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high blood pressure in SHR (18; 37). Thus, while the involvement of the sympathetic 
nervous system in HT is generally suspected, little is known about how the SNS actually 
participates in the development of the disease. Furthermore, in general, more is known 
about HT in male rats, but little is known about the disease in young female rats.  
The aim of our study was to explore the role of the SNS in both central arteries 
and peripheral vascular beds of young normotensive and hypertensive female rats. In 
conjunction with measures of PWV, we quantify C, K, and L in the hindlimb vascular bed 
of the spontaneously hypertensive rat (SHR) and thus examine the role of the SNS in 
regulating their values. With this approach we tested the hypotheses that a) vascular 
stiffness and viscoelasticity are under neurogenic regulation, and b) that this regulation is 
modified during the development of HT.  
 
 
 
Figure 4.1‒ Schematic of currently accepted (solid arrows) and proposed (dashed arrows) pathways for the effects of sympathetic 
nerve activity on mean arterial pressure.
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4.2 Methods 
Animals 
This protocol was approved by the Animal Use Subcommittee at the University of 
Western Ontario. Young female Wistar-Kyoto (WKY; 148±7g, n=7) and Spontaneously 
Hypertensive (SHR; 134±6 g, n=6) rats were used in this experiment (Charles River 
Laboratories, Montreal, Canada). Rats were housed in a light (12 h cycle) and temperature 
(22°C) controlled room in Plexiglas cages. Rats were allowed to eat (Prolab Rat chow, 
Mouse and Hamster 3000 Diet) and drink water ad libitum.  
Data Acquisition 
At approximately 7 weeks of age animals were anesthetized by an intraperitoneal 
cocktail of α-chloralose (80 mg/kg) and urethane (500 mg/kg) to ensure minimal impact 
on reflex cardiovascular control (19; 20). Once a surgical depth of anaesthesia was 
achieved, the right jugular vein and common carotid artery were exposed and cannulated 
with PE50 tubing to allow the delivery of dilute anaesthetic (α-chloralose 8-16 mg/kg/hr 
and urethane 50-100 mg/kg/hr) and measure arterial blood pressure (pressure transducer 
model MLT844, quad bridge amplifier model ML118; ADInstruments Colorado Springs, 
CO), respectively. Heart rate (HR; beats/min) was calculated online using R-R peaks 
from sub-dermal ECG electrodes (model FD-E2; Grass Technologies West Warwick, RI) 
and a vital signs monitor (model 78353B; Hewlett Packard Palo Alto, CA) was used in 
conjunction with blood pressure and temperature (rectally) to ensure that the animal 
remained at a stable surgical depth of anaesthesia throughout the experiment.  
A midline incision was made in the abdomen to expose the visceral organs. The 
right iliac artery was cannulated with PE50 tubing. The cannula was inserted rostrally to 
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measure blood pressure at the bifurcation of the aorta into the two iliac arteries. Aortic 
blood flow (QAorta) was measured just superior to the bifurcation of the aorta using a 
flowmeter (model TS420 Perivascular Flowmeter Module; Transonic Systems, Ithaca, 
NY) and Transonic flow probe (2.5 PSB). PWV was measured as described by Cosson et 
al. (5). Briefly, the time difference (T; seconds) between the diastolic foot of the pressure 
waveform at the carotid (proximal) and iliac (distal) arteries were measured. The distance 
(D; cm) between the catheter tips was measured post mortem, and PWV was calculated 
as (D/T; cm/s).  
The animals were allowed to recover from surgery for 1 hour. Baseline values 
were measured during a 10 minute period after which the neuronal nicotinic acetylcholine 
receptor agonist hexamethonium bromide (Hex; 25 mg/kg, Sigma-Aldrich, St. Louis, 
MO) was introduced systemically to abolish post-ganglionic neural activity. Once a new 
hemodynamic baseline was achieved, 10 minutes of data were recorded.  
Following data acquisition, animals were euthanized with an overdose of 
anaesthetic. Femoral arteries were harvested distal to the inguinal crease, cleaned of 
excess connective tissue, stabilized overnight in 15% sucrose, and then fixed overnight in 
10% neutral buffered formalin (HT501320, Sigma-Aldrich). Fixed arteries were mounted 
in clear frozen section compound (VWR, Cat. No. 95057-838) and snap frozen. Mounted 
arteries were sectioned (7µm) using a Lauda-Leitz (model 1720) digital kryostat, 
mounted on Fisherbrand Superfrost/plus microscope slides (Cat. No. 12-550-15), and 
stained using a Modified Verhoeff Van Gieson Elastic Stain Kit (HT25A, Sigma-
Aldrich). 
Data Analysis 
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Mean arterial pressure (MAP; mmHg), HR (beats/min), QAorta (mL/min), pulse 
wave velocity (PWV; cm/sec), and local compliance of the aorta (CLocal = [ΔQxΔT]/ΔP of 
the distal aorta; mL/mmHg, See Figure 3.1) were calculated. CLocal was used as a local 
measure of compliance at the level of the distal aorta. The vascular resistance (R) and 
mechanical properties (C, K and L) of the hindlimb vascular bed were assessed using the 
measured aortic flow and pressure waveforms in conjunction with a modified Windkessel 
model (41; 42). Briefly, the model predicts the flow waveform that would be produced by 
the measured pressure waveform. The predicted waveform is then compared with the 
measured flow waveform to determine the values of C, K and L (see Figure 1.5).  
Sections of femoral artery were visualized using a Zeiss Axiovert S100 
microscope, with a Sony Power HAD 3CCD colour video camera. Femoral artery wall 
thicknesses were measured using Northern Eclipse V8 (Empix Imaging Inc., 
Cheektowaga, NY, USA). 
Statistics 
The effects of rat strain (SHR/WKY) and drug (baseline/Hex) were compared 
using a mixed two way analysis of variance (ANOVA; SAS 9.1, Cary, NC, USA). Main 
effects of the ANOVA (SHR/WKY and baseline/Hex) were considered significant at 
P<0.05, and where interactions in the ANOVA were significant, again at P<0.05, 
Tukey’s post hoc analysis was used to identify differences. Wall thicknesses were 
compared using an unpaired, equal variance Student’s T-Test. Data are presented as mean 
± standard deviation. 
4.3 Results 
Hemodynamic alterations following Hex 
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The results confirm that the hypertensive animals used in the experiment had 
higher baseline MAP compared to WKY animals (Figure 4.2 I; P<0.05 at baseline). 
Following Hex, MAP fell in both strains (P<0.05) but to a larger extent in SHRs, 
resulting in similar MAP between strains (not significant; N.S. following Hex). QAorta was 
higher in the WKYs, (Figure 4.2 II; P<0.05); however, some of this difference can be 
attributed to the larger size of the WKYs compared to the SHRs (148±7g versus 134±6g, 
respectively; P<0.05). Systemic vascular resistance (R = MAP/QAorta) was greater in 
SHRs compared to the WKYs (Figure 4.2 III; main effect of strain; P<0.05), and Hex 
lowered R in both strains (main effect of drug; P<0.05). PWV was higher in SHR 
animals at both baseline and following Hex (Figure 4.2 IV; both P<0.05), but Hex caused 
a reduction in PWV in both strains (P<0.05).  
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Figure 4.2 ‒ Mean arterial pressure (MAP; I), caudal aortic flow (QAorta; II), caudal aortic 
vascular resistance (R; III) and pulse wave velocity (PWV; IV) from young female 
hypertensive (SHR) and normotensive (WKY) rats. Hex, hexamethonium. Values are 
mean ± standard deviation. *, Significantly different from baseline, P<0.05; †, 
Significantly different from WKY baseline, P<0.05; ‡, Significantly different from WKY 
Hex, P<0.05. Main effect statistics: a, denotes P<0.05 versus baseline; b, denotes 
P<0.05 versus WKY. 
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Mechanical alterations following Hex  
When compared with WKY, the SHR animals had lower C and CLocal (Figure 4.3 
I and 4.3 II respectively; main effect of strain P<0.05) and higher K values (Figure 4.3 
III; main effect of strain P<0.05). Compared with baseline, both C and CLocal increased 
only in the WKYs following Hex (Figure 4.3 I and 4.3 II respectively; P<0.05). 
However, Hex had little effect on C or CLocal in SHRs and failed to modify K in either 
strain (Figure 4.3 III; N.S.). Wall thickness for WKY (n=4) animals was 33.5±6.3µm 
versus 48.9±7.4µm in the SHR (n=4) (Figure 4.4; P<0.05; β=0.930). 
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Figure 4.3 – Hindlimb vascular bed compliance (C; I), local aortic compliance (CLocal; II) 
and viscoelasticity (K, III) of the lumped hindlimb vascular beds of young female 
hypertensive (SHR) and normotensive (WKY) rats. Hex, hexamethonium. Values are 
mean ± standard deviation.*, Significantly different from baseline, P<0.05; †, 
Significantly different from WKY baseline, P<0.05 ‡, Significantly different from WKY 
Hex P<0.05. Main effect statistics: b, denotes P<0.05 versus WKY 
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Figure 4.4 ‒ Ex vivo, unpressurized femoral artery wall thickness from young female 
hypertensive (SHR) and normotensive (WKY) rats. Top: group averages of SHR and 
WKY animals. Bottom: representative SHR (left) and WKY (right) ex vivo unpressurized 
femoral arteries at 20X magnification. †, Significantly different from WKY, P<0.05. 
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4.4 Discussion 
The purpose of this study was to examine the role of the SNS in the central 
arteries and peripheral vascular beds of young normotensive and hypertensive female 
rats. It was observed that the lumped compliance of the hindlimb vasculature of young 
female WKY animals increased following ganglionic blockade, indicating that peripheral 
vascular stiffness was affected by SNS input. By contrast, it was observed that SHRs had 
lower C and higher K, meaning stiffer peripheral vascular beds with higher resistance to 
stretch, both before and following ganglionic blockade. Thus, it appears that the normal 
neurogenic control of vascular stiffness is lost in the developmental period of SHR (i.e., 
within 7 weeks of age). This loss of neurogenic control was associated with vascular 
remodeling in the SHR, again, at the early age of 7 weeks. These data support the overall 
hypothesis that vascular stiffness is under some level of neurogenic control but that this 
control is modified in the developmental stages of HT in females. 
Previously, it was demonstrated that brachial artery compliance of humans (33) 
and the lumped compliance of the entire human forearm vascular bed (41) are under 
some neural control, where sympathoexcitatory reflex maneuvers consistently reduced C. 
The current results from a rodent model provide new experimental evidence that the 
compliance (C and CLocal) of peripheral vascular beds are (normally) under some neural 
control as well, supporting these earlier results from humans. However, the current 
results show further that this neural control of vascular stiffness and viscoelasticity 
appears to be “lost” in HT. This observation supports the scenario proposed in Figure 4.1 
whereby reduced compliance and increased viscoelasticity, possibly due to the trophic 
actions of neurotransmitters (7; 43), add to hypertension by means of faster wave 
 
105 
reflections reaching the aorta during systole which increases the afterload of the left 
ventricle (30).  
It is particularly important that the value of K in SHR was found to be higher than 
that observed in the WKY group because this property represents viscoelastic resistance 
to stretch within the vessel wall which is over and above that of pure elasticity. While the 
concept of viscoelasticity is not new (28), the components of the vessel wall that account 
for changes in this important mechanical property, or differences among populations, 
remain largely unknown. Yin and colleagues (39) observed differences in the viscoelastic 
properties such as the stiffness modulus and phase lag (force-length relationships) in 
young and senescent arterial strips from dogs. They noted that although the stiffness was 
increased in the senescent animals, the differences observed could not be accounted for 
by changes in the content of elastin, collagen, or the ratio of the two. Our results suggest 
that vascular remodeling (at least in Ex vivo, unpressurized femoral arteries) may play a 
role in augmenting K.  
Finally, the dichotomy between the roles of central arteries versus peripheral 
vasculature in the control of blood pressure deserves emphasis. It is well accepted that the 
resistance of the central vessels makes up a negligibly small part of total resistance 
because of their relatively large diameters. On that basis, it is reasonable to suspect that 
central vascular radii are not under acute SNS control, although it is known that the SNS 
exerts chronic (trophic) effects on all vascular beds, which can lead to vascular 
remodeling (7). The question then arises as to whether the compliance and viscoelasticity 
of the central arteries are also under these trophic effects or under SNS control. The wall 
thickening observed in the femoral artery, the higher PWV following Hex, and the 
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increased stiffness in the distal aorta, as measured by CLocal, all point to a remodeled 
vascular system that is not necessarily confined to the peripheral vasculature. Thus, by 7 
weeks of age, there is progressive remodeling present in the SHR model. It is likely that 
the mechanisms of such remodeling include pressure-induced hypertrophy and the 
trophic effects of chronic SNS activity. The way in which these factors combine to 
induce the stiffening and remodeling observed in HT remains unknown. However, our 
study supports the potential role of the SNS in the pathogenesis of HT. 
Limitations 
The interpretation of the results obtained here is based on the assumption of 
complete neural blockade by Hex. The fall in R and MAP following ganglionic blockade 
with Hex provide evidence of ganglionic antagonism. Also, the dose of Hex used here 
was higher than that of previously published reports (16; 36) in which 20mg/kg of 
intravenous Hex abolished (renal) sympathetic nerve activity in both SHR and WKY 
animals between 15 and 20 weeks of age.  
Additionally, because of the observed falls in MAP following Hex, changes in C 
might reflect a shift along the same pressure-volume curve, and may not be indicative of 
an actual change in the mechanical properties of the vasculature (i.e. shift of the pressure-
volume curve). 
4.5 Conclusions 
The current results indicate that vascular compliance of the peripheral vascular 
bed is regulated in part by the nervous system but that this control is lost in SHR in 
conjunction with vascular remodeling. The way in which the remodeled vascular bed and 
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aorta affect this neurogenic regulation is not known, but it was noted that this altered 
neurovascular control was evident already by 7 weeks of age in the SHR group.  
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Chapter 5 ‒ Evidence for sexual dimorphism in sympathetic control of 
vascular function. 
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5.1 Introduction 
The preceding chapters have outlined studies which examined the role of the 
sympathetic nervous system (SNS) in the early stages of hypertension (HT). The designs 
of the studies were limited to either male or female animals as there was no initial 
intention to include male/female comparisons. However, during data collection and 
analysis of the studies, striking differences were observed in the hemodynamic and 
hindlimb mechanical properties of the male and female rats. In particular, female animals 
exhibited higher baseline heart rate (HR) and mean arterial pressure (MAP), but the most 
striking differences were lower levels of hindlimb compliance (C), and local aortic 
compliance (CLocal), with much higher viscoelasticity (K). In essence, female animals 
appeared to have much stiffer peripheral vascular beds compared to their age matched 
counterparts. 
Sex differences have been reported in a number of (patho-) physiologic conditions 
including incidence of cardiovascular disease, systemic inflammation, systemic lupus 
erythematosus and type-2 diabetes (3; 4; 7; 21). Recently, Hart et al. (11) demonstrated 
that the relationships between muscle sympathetic nerve activity, cardiac output and 
vascular resistance, relationships that are often seen in males, break down in females. 
Similarly, females exhibit less vascular responsiveness to intra-arterial infusions of 
norepinephrine compared to males (18), and observations from rodent studies suggest 
that, in contrast to males, females lack baseline neuropeptide Y (NPY)-mediated control 
of hindlimb vascular conductance (12-14). Additionally, chapters 3 and 4 indicate that the 
mechanical properties of the rat hindlimb are regulated by the SNS, but the magnitude of 
the differences observed in the values C, CLocal and K between males and females are 
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striking. These examples of sexually dimorphic regulation by the SNS suggest that male 
and female animals may utilize different mechanisms of vascular control. Therefore the 
purpose of this study was to explore the differences observed in the systemic 
hemodynamics and hindlimb vascular mechanics of male and female rats, and how neural 
cardiovascular regulation might differ between the sexes. 
5.2 Methods 
A retrospective analysis of data from chapters 3 and 4 was performed in which the 
hemodynamic and lumped hindlimb vascular mechanics of male and female rats was 
assessed for sex-based differences. Spontaneously hypertensive (SHR; male n=10, female 
n=7) and Wistar-Kyoto (WKY; male n=6, female n=7) rats from both sexes underwent 
identical anaesthesia and surgical procedures as previously outlined (chapters 3 and 4). 
Briefly, the animals were anesthetized with an intraperitoneal injection of urethane 
(500mg/kg) and α-chloralose (80mg/kg). Animals were instrumented to measure blood 
pressure at the carotid artery, and at the bifurcation of the aorta into the iliac arteries. 
Blood flow was measured just superior to the bifurcation of the aorta. 
Mean arterial pressure (mmHg), HR (beats/min), aortic blood flow (QAorta, 
mL/min), caudal conductance (CondCaud, mL/min/mmHg), pulse wave velocity (PWV, 
cm/s) and CLocal (mL/mmHg) were calculated (see chapters 3 and 4). The vascular 
resistance (R) and mechanical properties (C, K and L) of the hindlimb vascular bed were 
also assessed (see chapters 3 and 4). C and CLocal were normalized to body weight to 
account for differences in the volume of vasculature tissue between the sexes. All 
variables were measured or calculated at baseline and following the administration of 
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hexamethonium bromide (Hex; 25mg/kg) to abolish post-ganglionic neural transmission. 
All animals were 7 weeks of age at the time of the surgical interventions.  
Statistics 
Data were analyzed at baseline and during Hex using a mixed two-way Analysis 
of Variance (ANOVA; SAS 9.1, Cary, NC, USA) on sex (male/female) and strain 
(SHR/WKY). The response to Hex was compared to baseline using a paired Student’s t-
test. Main effects of the ANOVAs and t-test were considered significant at P<0.05, and 
Tukey’s post hoc analysis was used to identify where differences occurred in the 
ANOVA. Data are presented as mean ± standard deviation. 
5.3 Results 
Baseline hemodynamics and body weight can be found in Table 5.1. Main effects 
of sex and strain were observed for MAP, HR, QAorta, CondCaud, and R (all P<0.05). 
MAP, HR and R were higher in SHRs versus WKYs and in females compared to males. 
Aortic blood flow and CondCaud were lower in SHRs versus WKYs and were higher in 
males. Figure 5.1 depicts PWV (Figure 5.1, I), weight normalized C and CLocal (Figure 
5.1 II and III, respectively) and lumped hindlimb K (Figure 5.1, IV). Compared with 
WKY PWV was higher in SHRs (main effect of strain, P<0.05) but was not different 
between the sexes. Females displayed lower C and CLocal compared to males (main effect 
of sex, P<0.05); however, the difference in C was abolished when normalized to body 
weight (CLocal remained lower in females). C and CLocal were lower in SHRs (main effect 
of strain, P<0.05) and this difference remained following normalization. Females had 
higher K values compared to males (interaction effect, P<0.05) and in SHRs were higher 
than WKYs (interaction effect P<0.05).  
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Response to Hex 
The percent change from baseline for MAP, HR, QAorta, CondCaud and R can be 
found in Table 5.2. Mean arterial pressure fell in response to Hex in all groups except 
male WKYs (t-test, P<0.05). Heart rate rose in all groups except female SHRs following 
Hex (t-test, P<0.05). Aortic flow fell in female SHRs only (t-test, P<0.05), while 
CondCaud rose and R fell in both male and female SHRs (t-test, P<0.05).  
Pulse wave velocity fell in all groups following Hex (t-test, P<0.05; Figure 5.2 I). 
The weight corrected hindlimb C and CLocal rose in all groups except Male WKYs (t-test, 
P<0.05; Figure 5.2 II and III respectively) and K fell in all groups except female SHRs (t-
test, P<0.05; Figure 5.2 IV). 
Comparisons in Hex 
Following Hex administration the SHRs animals had a larger change in MAP 
compared to WKYs (main effect of strain, P<0.05) and female animals had a greater fall 
compared to males (main effect of sex, P<0.05).The increase in HR was greater in male 
animals compared to females (main effect of sex, P<0.05). A significant interaction of 
sex and strain was seen in QAorta, CondCaud and R following Hex, in that male SHRs and 
WKYs were significantly different from one another in each variable. Additionally, QAorta 
was significantly different between male and female SHRs, and R was significantly 
different between male and female WKYs (all P<0.05). PWV fell more in males than in 
females (main effect of sex, P<0.05) and there were no differences in the response to 
Hex in any group for C, CLocal, or K.  
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Table 5.1 ‒ Weight (g), mean arterial pressure (MAP), heart rate (HR), aortic flow 
(QAorta), caudal conductance (CondCaud) and caudal resistance (R) in male and female 
spontaneously hypertensive (SHR) and Wistar-Kyoto (WKY) rats.  
 
Male Female 
SHR (n=10) WKY (n=7) SHR (n=6) WKY (n=7)
Weight (g) 207±16 a 214±15 134±6 a,b 148±7 b 
MAP (mmHg) 86±13 a 64±5 91±6 a,b 78±7 b 
HR (beats/min) 339±29 a 302±81 388±24 a,b 333±25 b 
QAorta (mL/min) 5.7±2.0 a 9.5±3.2 2.7±0.6 a,b 5.7±2.3 b 
CondCaud (μL/min/mmHg) 68±26 a 147±43 30±6 a,b 75±35 b 
R (mmHg/mL/min) 17.6±7.0 a 7.7±3.3 31.5±7.1 a,b 15.4±5.7 b
All of the variables listed have significant main effects of sex and strain (both 
P<0.05). Values are mean ± standard deviation. Main effect statistics: a, P<0.05 
versus WKY; b, P<0.05 versus male. 
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Figure 5.1‒ Pulse wave velocity (PWV; I), weight normalized hindlimb compliance (C; 
II), weight normalized local aortic compliance (CLocal; III) and lumped hindlimb 
viscoelasticity (K; IV) from male and female spontaneously hypertensive (SHR) and 
normotensive Wistar-Kyoto (WKY) rats. Values are mean ± standard deviation. * 
denotes P<0.05 versus WKY (within a sex), † denotes P<0.05 versus male WKY; ‡ 
denotes P<0.05 versus male SHR. Main effect statistics: a, P<0.05 versus WKY; b, 
P<0.05 versus male.  
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Table 5.2 ‒ Percent change from baseline following ganglionic blockade with 
hexamethonium bromide (Hex; 25mg/kg) on mean arterial pressure (MAP), heart rate 
(HR), aortic flow (QAorta), caudal conductance (CondCaud) and caudal resistance (R) in 
male and female spontaneously hypertensive (SHR) and Wistar-Kyoto (WKY) rats. 
 
Male Female 
SHR WKY SHR WKY 
MAP (% Δ) -11±13†a 4±9 -28±7†a,b -17±7†b 
HR (% Δ) 9±7† 26±12† -4±7b 7±6†b 
QAorta (% Δ) 22±36† -5±28 -14±13† -6±18 
CondCaud (% Δ) 36±37†* -9±24 19±17† 14±23 
R (% Δ) -24±16†* 14±28 -11±14† -14±17 
Main effect of sex and strain for MAP, main effect of sex for HR and interaction effect 
for CondCaud, QAorta and R (all P<0.05). Values are mean ± standard deviation. † denotes 
significantly different from baseline (t-test, P<0.05). * denotes P<0.05 versus WKY 
(within a sex). Main effect statistics: a, P<0.05 versus WKY; b, P<0.05 versus male.  
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Figure 5.2 ‒ Percent change from baseline of pulse wave velocity (PWV; I), weight 
normalized hindlimb compliance (C; II), weight normalized local aortic compliance 
(CLocal; III) and lumped hindlimb viscoelasticity (K; IV) from male and female 
spontaneously hypertensive (SHR) and normotensive Wistar-Kyoto (WKY) rats 
following ganglionic blockade with hexamethonium bromide (Hex; 25mg/kg). Values are 
mean ± standard deviation. † denotes significantly different from baseline (t-test, 
P<0.05). Main effect statistics: b, P<0.05 versus male. Note that CLocal had a significant 
interaction, however no group differences were identified in the post hoc analysis. 
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5.4 Discussion 
The main finding of the current study was that female rats have higher resistance 
(R) and viscoelasticity (K) in peripheral vascular beds relative to age-matched males. 
Some of the dimorphism was driven by the SNS, but other factors also play a role. Sexual 
dimorphism was particularly evident in baseline MAP, HR, R, CLocal and K. These sex-
dependent differences were apparent in both normotension and HT indicating that they 
are not strain dependent.  
Higher MAP in female animals, compared with male animals, was present in both 
SHRs and WKYs and was largely mediated by neural input in females and in HT. Male 
WKYs showed no change in MAP following Hex, but showed marked tachycardia. 
Conversely, female SHRs had a large fall in MAP with no change in HR following Hex. 
These divergent responses suggest different control mechanisms in male and female rats, 
which become amplified in female HT. Specifically, male normotensive rats display 
parasympathetic (PNS) control of the heart at baseline as ganglionic ablation increased 
HR in accordance with PNS withdrawal (10; 19). In contrast, female hypertensive rats 
appear to have altered autonomic control of the heart at baseline, in that ganglionic 
blockade had no effect on HR. The large fall in MAP with Hex in female SHRs was not 
accompanied by a large fall in R as QAorta declined modestly. This latter observation 
suggests reduced cardiac contractility with Hex in the female SHR animals, rather than a 
PNS withdrawal mechanism.  
The observed high R and low CLocal in female rats mirror human data from our lab 
(37). In this earlier study, using the same mathematical model, young subjects and HT 
patients were analyzed. The females (regardless of group) displayed higher R and lower 
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C relative to males. Also, K was markedly higher in the human HT patients (37) which 
parallels the results presented here in the SHR model. To date, no one has reported sex 
differences in vascular viscoelastic properties. The results presented here show striking 
sex differences in the viscoelasticity, which represents the resistance to stretch in the 
blood vessels. This property of the vessel wall is not well understood in either health or 
disease. It is apparent that viscoelasticity is calcium dependent (28; 29) indicating that the 
cross-bridge attachment within vascular smooth muscle cells (VSMC) is a key factor in 
its regulation. The current study also emphasizes that the SNS can influence K and that 
the control is modified by sex and in disease (i.e. female SHR). Such differences may be 
influenced by sex-dependent differences in VSMC structure and signaling cascades (16; 
22). Specifically, reduced Ca2+ handling and a blunted expression and activation of 
protein kinase C (PKC) in VSMCs from female animals, leads to less contraction relative 
to male animals. How these alterations affect K, or its regulation, remains unclear. 
Estrogen is a likely candidate mediating the sexual dimorphism seen here. The 
role of estrogen in regulating vascular stiffness is complex. Reports of both increased and 
reduced levels of vascular stiffness by estrogen supplementation have been reported (25; 
26; 32; 35). Further, estrogen manipulation does have the ability to alter resting VSMC 
structure, intracellular Ca2+ concentrations and PKC expression to levels that are similar 
to males (16; 22; 24). Indeed these results are further confounded, as the type of estrogen 
used, the method of delivery and previous estrogen exposure all influence the outcome 
(8; 31). Despite these conflicting reports, estrogen does impact vascular stiffness, and 
does impact sympathetic vascular control (36; 38; 39). 
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To further address the direct effect of estrogen, a secondary study was performed 
on small groups of female animals in which estrogen levels were manipulated by 
ovariectomy (OVX; n = 6) and ovariectomy + estrogen replacement (OVX+E2; 0.25mg 
17β-estradiol [3-week release]; n = 6). The data are provided in Appendix A.2. Briefly, a 
main effect of estrogen manipulation was observed in C and a strain x estrogen 
interaction was observed for PWV. Neither OVX, nor OVX+E2, had altered hindlimb 
mechanics relative to intact controls in either strain of rat. However, point-wise 
comparisons between OVX and OVX+E2 suggest that OVX tended to reduce indices of 
stiffness (C and PWV), while OVX+E2 tended to increase stiffness, particularly in HT. 
A main effect of strain was observed for MAP and again when point wise comparisons 
were made, OVX had lower MAP compared to OVX+E2 in SHRs. These results suggest 
that estrogen is an important factor in regulating the increased stiffness seen in female 
rats, at least in SHRs. However, it is clear that dosages of estrogen replacement must be 
titrated carefully in order to properly mimic the intact animal. 
5.5 Perspectives 
The sexual dimorphism of vascular bed mechanics reported here, combined with 
reports of similar sex-specific differences in vascular reactivity to sympathetic stimuli 
(12; 13; 18), suggest that female animals may rely on different mechanisms to regulate 
vascular function. Males appear to sympathetically control vessel diameter (i.e. 
alterations in vascular resistance) to regulate blood pressure, while the stiffer vasculature 
seen in female animals suggests a greater reliance on central (or cardiac) mechanisms. 
This mechanism has been observed previously, when, in response to lower body negative 
pressure (5) and progressive tilt (27), females demonstrate an exaggerated heart rate 
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response, and lower sympathetic nerve activation, despite the same level of 
hemodynamic stress. Additionally, females have shown greater cardiac responsiveness 
versus peripheral vascular reactivity to a variety of stressors (1; 9), and exhibit 
exaggerated vascular contraction to non-adrenergic/sympathetic antagonists (6; 30; 33) 
compared to males.  
Female rats appear to lack the NPY mediated control of baseline hindlimb 
conductance which is present in males (12; 13). Estrogen appears to be involved in 
regulating the (lack of) NPY response in females. Recent work by Jackson et al. (15) 
examined the sympathetic hindlimb conductance response in female Sprague Dawley rats 
that were either intact, were ovariectomized, or were ovariectomized but had 
supplemental estrogen. They reported that following ovariectomy, the expression of both 
NPY and the NPY Y1 receptor (Y1R) were increased, as was the Y1R control of hindlimb 
vascular conductance. These adaptations were prevented by the supplementation of 
estradiol (15) suggesting that estradiol plays a critical role in regulating sympathetic 
cardiovascular control.  
In the vasculature NPY produces a potent and long lasting vasoconstriction and 
potentiates the effects of norepinephrine (20; 34). In male animals, based on the increased 
hindlimb conductance response to Y1R antagonism, we can presume that these 
contractions are present at baseline (14) and may act to stabilize the vasculature over 
many cardiac cycles. The stiffer vasculature observed in females would work in much the 
same fashion, buffering beat-to-beat fluctuations, with little need for neural input. Thus, 
the need for NPY mediated baseline control of the hindlimb is absent and the system is 
down regulated (12; 13), and may account for the lower level of baseline sympathetic 
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nerve activity that is commonly observed in females (Figure 5.3), as stiffer arteries would 
require less neural input. 
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Figure 5.3 ‒ Matched female (A) and male (B) baseline neurograms of muscle 
sympathetic nerve activity (MSNA) measured in the peroneal nerve. Data generously 
provided by Ruma Goswami.  
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Limitations 
The dichotomous mechanisms of cardiovascular regulation proposed here are 
based on a limited number of observations in a young rodent population. Thus, the 
phenomenon mentioned may be the result of differences of the natural development of 
male and female animals, and may not reflect a distinct sex difference. Indeed, increased 
levels of endogenous estrogen and testosterone in males and females, respectively, have 
been associated with altered vascular stiffness in pre- versus post-pubertal humans (2). 
As the animals here were post-pubescent (17; 23) it is unlikely that the endogenous levels 
of estrogen and/or testosterone factored into the differences seen, although measurement 
of endogenous estrogen and testosterone is required for confirmation. Additionally, as the 
animals were measured at the same age (instead of weight), were housed in the same 
location and exposed to the same diet, it is unlikely that environmental or developmental 
factors can account for the increased stiffness observed in female animals. Much more 
work is required in order to ascertain whether the increased stiffness in female animals is 
a physiologically relevant mechanism of cardiovascular control.  
5.6 Conclusions 
 This retrospective analysis of data presented in chapters 3 and 4 suggests that 
dichotomous mechanisms of cardiovascular control exist between male and female 
animals. Female animals exhibited augmented MAP and HR relative to males in 
conjunction with greater stiffness and viscoelasticity in both SHR and WKY animals. 
The impact of K on blood pressure control is unknown, but this parameter may be a 
critical feature in female hypertensive animals.  
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Differential control of the heart in male and female animals is suggested 
following ganglionic blockade and an increase in compliance and reduced K following 
Hex suggest that both of these variables are affected by agonist-induced intracellular 
calcium levels. The more compliant vascular beds of male animals may require greater 
neural input to maintain vascular homeostasis compared to the stiffer female animals. 
Females apparently rely on central (cardiac) mechanisms to regulate blood pressure, 
while males would rely on sympathetically mediated changes in vessel caliber to alter 
vascular resistance. It may be that these differences are due to altered vascular mechanics 
(or vice versa).  
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6.1 Overall Summary 
The primary aim of this body of research was to explore the role of the 
sympathetic nervous system (SNS) in regulating the cardiovascular system during the 
development of hypertension (HT). Through the actions of both norepinephrine (NE) and 
neuropeptide Y (NPY), the SNS elicits both acute and chronic effects on the vasculature. 
Much is known about how these neurotransmitters interact with the vasculature during 
both normotension and developed HT, but the way in which these critical 
neurotransmitters control the vasculature as HT develops remains unclear. 
The SNS’s involvement in HT fundamentally occurs through heightened 
sympathetic activity leading to increased vascular resistance (3; 18). NE and the α-
adrenergic receptor (α-AR) are the classic mediators of the augmented resistance (10; 
32). Data presented in chapter 2 highlight an exaggerated role for the NPY-mediated 
signaling in the early stages of the HT (at least in male animals). This enhanced NPY-
mediated control was absent at 3-5 weeks of age, but present at 7 weeks, suggesting that 
alterations in sympathetic signaling mechanisms occur rapidly in developing HT. 
Additionally, greater expression of the NPY Y1 receptor (Y1R) was observed in skeletal 
muscle extracts from 7-week old SHRs, with no change in markers of adrenergic 
innervation (α-AR and tyrosine hydroxylase). These data suggest that adrenergic 
mechanisms do not contribute to HT at this age. The enhanced regulation of hindlimb 
conductance by NPY in SHRs suggests that NPY and the Y1R are involved in the 
development of HT.  
A hallmark of hypertension is vascular remodeling which is characterized by 
vascular stiffening and hypertrophy (3; 11; 24). NPY has been linked to vascular 
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remodeling (1); yet the role of the SNS in regulating vascular stiffness remains 
speculative. Using a modified Windkessel model, chapters 3 and 4 demonstrate that the 
SNS is actively involved in the regulation of hindlimb vascular stiffness in male and 
female rats. This stiffness was augmented in HT in both sexes; however, antagonism of 
the Y1R produced no appreciable change in the measured stiffness in males, while 
ganglionic ablation reduced stiffness in both sexes. Assessment of the Y1R control of 
vascular stiffness in females was not performed for two reasons. First, research from our 
lab has demonstrated that NPY plays little role baseline cardiovascular control in females 
(12; 13). Secondly, no effect was observed by Y1R antagonism in males; therefore, it was 
deemed unnecessary to examine the response in females. It is important to point out that 
the regulation of the mechanical properties of the rat hindlimb appear to be different 
between males and females in both normotension and hypertension (Figure 6.1). 
Specifically, normotensive males (at least at 7 weeks of age) appear to regulate C and K 
through the sympathetic nervous system, but not R. In contrast, sympathetic mechanisms 
affect R and C in normotensive females without affecting K. Hypertension alters the 
control in both males and females but in different ways. Male hypertensive animals retain 
the neural control of C and K but gain control of R, while female animals lose the ability 
to regulate C likely because of vascular remodeling, but retain control of R. These 
differences highlight the dimorphism between males and females in vascular regulation 
in both normotension and HT, but also underscore our limited understanding of its 
complexity.   
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Figure 6.1 ‒ Updated schematic depicting the mechanisms of control in both male and 
female normotensive and hypertensive rats. See text for details. Dotted line represents 
apparent lack of control (in males), dashed lines are speculated, but were not measured 
(in males), and bolded appear to be augmented/dysregulated (in females). 
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Neuropeptide Y and the Y1R influence baseline vascular control in males (14), as 
antagonism of the Y1R increased hindlimb vascular compliance. Chapter 3 demonstrated 
that Y1R blockade did not alter vascular resistance. However, the measurements of 
arterial pressure and flow here were made at the level of the aorta, versus the femoral 
artery as in chapter 2. Vascular resistance reflects only the steady state component of 
blood flow and acts through alterations in vessel diameter (25). Thus, the resistance of the 
central vessels makes up a negligible part of total resistance, because of their relatively 
large diameters, and it is reasonable to suspect that central vascular radii are under less 
SNS control (31). Therefore, alterations in aortic flow following Y1R antagonism were 
not expected.  
The augmented vascular stiffness seen in female animals forms the basis for the 
proposed sex-associated differences in cardiovascular regulation outlined in chapter 5. 
The stiffer vascular beds of female animals suggests that female animals may rely on 
mechanical rather than chemical regulation of the vasculature. Alteration of the stiffness 
of the vasculature rather than the diameter of the blood vessels may increase the 
contribution of changes in heart rate and cardiac contractility to regulate blood pressure. 
This cardiac mechanism has been suggested previously. Using both lower body negative 
pressure (7) and progressive tilt (29), females preferentially induce tachycardia rather 
than increased vascular resistance. Additionally, reflexive increases in muscle 
sympathetic nerve activity are blunted relative to males, which is consistent with 
parasympathetic withdrawal occurring prior to sympathetic activation in the heart (8; 19; 
28).  
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Finally, hypertensive animals, both male and female, exhibited markedly stiffer 
vessels compared to their normotensive counterparts. This observation was expected. 
However, the fact that only the female hypertensive animals appeared to have lost the 
neurogenic control over the vascular stiffness, is intriguing. Perhaps the augmented 
stiffness imposed by the hyper-adrenergic state that characterizes hypertension (10; 32; 
36) irreversibly stiffens the vasculature through remodeling, thereby preventing it from 
relaxing. The mechanistic and teleology for this sex-based difference in SHR animals are 
not known. Regardless, these data clearly demonstrate that in hypertension sex 
differences in cardiovascular control are present.  
 In conclusion, two major themes are evident from this body of work. First, altered 
neurovascular regulation during the early stages of HT is evident. Secondly, the ways in 
which male and female animals regulate the cardiovascular system appear to be 
fundamentally different. Expanding on the first finding, enhanced NPY mediated 
hindlimb vascular conductance was observed in 7-week old male SHRs. These in vivo 
observations were supported by an increased expression of Y1R in red vastus 
homogenates from SHR while α-AR mechanisms were comparable to WKY control 
animals. The increased vascular resistance and stiffness in the SHR were 
sympathetically-mediated in both sexes, but NPY and the Y1R do not appear to be 
involved. The augmented vascular stiffness in females relative to males was the first 
indicator of the sexual dimorphism of cardiovascular control. Coupled with the lack of 
baseline NPY/Y1R control (12; 13) and the modulation of sympathetic control with 
ovariectomy (15), a situation arises whereby the stiffer vasculature of female animals 
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would allow changes in heart rate to maintain blood pressure, while male animals utilize 
increases in vascular resistance.  
6.2 Limitations 
A major limitation of this dissertation is the absence of measured sympathetic 
nerve activity. Measurement of either renal or lumbar sympathetic nerve activity is 
routinely done in the literature. Much of this dissertation assumes that sympathetic 
outflow is elevated in the SHR animals. This assumption has been validated previously 
(see (9) for a detailed review), yet direct measurement here would strengthen our 
conclusions. Additionally, a direct measurement of sympathetic nerve activity would 
have allowed us to verify that the hexamethonium produced a complete ganglionic 
blockade. We can reasonably assume that complete ganglionic blockade occurred with 
hexamethonium as previously published reports (16; 30) indicate that 20mg/kg was a 
sufficient dose to completely block ganglionic neural transmission as measured in the 
renal nerve in both SHR and WKY animals.  
A second limitation here is rooted in the fact that the dichotomous mechanisms of 
cardiovascular regulation being proposed are based on a finite number of observations 
from different data sets. While precautions are taken to ensure consistency between 
experiments, random variations are assured. The stiffness data presented were collected 
such that experiments were run on half of the female animals followed by all of the male 
animals, and finally the second half of the females. The unique timing of data collection 
reduces the likelihood of bias in data collection (i.e. surgical precision) and bolsters our 
confidence in the observations.  
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Third, there is a possibility that the responses seen in an anaesthetized rat are not 
physiological, due to blunted reflex control. This is a valid argument, and with many 
barbiturate and gas forms of anaesthesia this holds true (23; 34). Here, a mixture of 
urethane and α-chloralose was utilized as this cocktail has been shown to maintain reflex 
cardiovascular control (20; 21). Additionally, data from our lab (Usselman et al., In 
Press) indicates that this cocktail does not impair autonomic reflexes, as both light and 
deep levels of anaesthesia did not impair sympathetic reflexes in response to lower body 
negative pressure in rats.  
As outlined in chapter 1, the RCKL model relies on pressure-volume relationships 
to estimate the mechanical properties of the vasculature. Primarily, because these 
properties represent the vasculature as a whole, we are unable to ascribe a specific level 
of the vascular tree to a given component of the model (35). Additionally, a large 
proportion of the resistance in the model is generated by resistance arterioles, but it is 
unclear from the model how these vessels also contribute to the compliance of the 
vascular bed. Further, the four components of this model represent an over simplification 
of a complex physiologic system giving us a method to conceptualize the mechanical 
properties. Additionally, because of the observed falls in MAP following Hex, changes in 
C might reflect a shift along the same pressure-volume curve, and may not be indicative 
of an actual change in the mechanical properties of the vasculature (i.e. shift of the 
pressure-volume curve). 
Finally, as the majority of the data were collected from adolescent animals, it can 
be argued that the differences observed are due to variations in the growth patterns of the 
animals and are therefore artifacts of the normal growth process. It is unlikely that the 
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differences are artifacts, as the majority of animals tested were measured at the same 
absolute age of 7 weeks. This age was chosen for two specific reasons. First, at the same 
absolute age, WKY animals are heavier than SHR animals. Therefore had the animals 
been matched by weight, as is often done, the WKY animals would have represented a 
younger population of animals compared to the SHRs. Similarly, comparisons between 
the sexes would be invalid, as weight matched females would be older relative to the 
males. Secondly, at 7 weeks of age mild HT is evident in SHRs while other co-
morbidities, such as heart disease, dyslipidemia or insulin resistance, are absent (4; 6; 
27). Thus, matching the age of the animals allows for between group comparisons with 
little chance of growth artifact or co-morbidities factoring into the observations.  
6.3 Future Directions 
 This dissertation outlines our attempts to understand the role of the SNS during 
the development of HT. It highlights some key alterations in the vascular response to 
sympathetic innervation, yet much work needs to be completed to broaden our 
understanding of how these two critically integrated systems are regulated. 
 A critical first step needs to be to integrate neural recordings into the 
methodologies described herein. Technological advances have led to the development of 
in-dwelling telemetric devices, which allow for the continuous measurement of two 
separate variables (i.e. blood pressure and sympathetic nerve activity). Using these 
devices tocollect data from conscious animals eliminates any anesthetic effects and 
allows for a longitudinal assessment of sympathetic hyperactivity and arterial pressure 
augmentation. Furthermore, the effectiveness of interventions designed to either raise or 
lower sympathetic activity (or blood pressure) can be evaluated.  
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 A role for NPY and the Y1R in the early stages of HT is implicated (chapter 2), 
yet much work is required to ascertain the mechanisms responsible for this enhanced 
regulation. To gain better insight into the roles of NPY and the Y1R in HT, chronic 
receptor agonism/antagonism studies are required. Examining the molecular, cellular and 
hemodynamic responses to chronic agonism/antagonism will help expose some the 
mechanisms governing the development of HT. 
 The involvement of eatradiol (E2) in both sympathetic and cardiovascular 
development is known (2; 5; 33). Characterizing E2’s role in regulating the mechanical 
properties of the vascular wall and how the SNS functions differently during chronic (8-
12 week) E2 manipulation, is unknown. Additionally, E2 supplementation in the form of 
a continuous release pellet does not mimic the natural 4 day cycle of the rat (17; 26). 
Thus, a more physiologic study of E2 should be made, which accounts for the cyclic 
nature of this important hormone. Further, exploring how E2 and androgen manipulation 
in male rats affects both the sympathetic and cardiovascular systems is required. 
 Chapter 5 of this dissertation proposes a novel mechanism of cardiovascular 
control in young female rats. This supposition was based on a limited number of 
observations; therefore a thorough investigation of this phenomenon should be made. In 
order to ascertain whether female animals rely on central (cardiac) versus peripheral 
(vascular resistance) mechanisms to maintain blood pressure during times of stress, 
selective blockade of the heart and blood vessels is required. Selectively antagonizing 
different aspects of the autonomic nervous system will allow for clarification of the 
precise roles they have in cardiovascular regulation.  
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6.4 Final Remarks 
 The involvement of the SNS in the development of HT is known and accepted (9; 
22), yet the alterations in sympathetic control that occur early in the pathogenesis are less 
well understood. We have shown that alterations in NPY signaling and the Y1R precede 
changes in the adrenergic system. Additionally, the increased stiffness that is observed in 
HT begins very early in the process, does not involve the Y1R and is a regulated property 
of the vasculature that appears to be defective in female HT animals. Finally, the sex-
associated differences in vascular stiffness and the regulation of the mechanical 
properties of the vasculature may highlight a novel mechanism of vascular control in 
young male and female animals. Evidence supporting this theory is mounting; however, 
much work needs to be done to confirm these suppositions.  
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Appendix A ‒ Supplementary Data 
Chapter 3‒ Femoral Flow Variability 
Figure A.1 depicts the fluctuations in femoral flow observed in the female 
animals compared to male animals. The fluctuations were independent of changes in 
pressure, heart rate and temperature. The flow would rise for 2-3 minutes and would then 
fall. There was never a prolonged period of stability which prevented a stable baseline 
from being collected. 
Figure A.2 illustrates the variability among intact female animals, female animals 
that were ovariectomized (OVX), ovariectomized + estrogen replacement (OVX+E2; 
0.25mg 17β-estradiol [3-week release]) and male animals. The coefficient of variation 
(CoV = standard deviation/mean) for hindlimb conductance (CFem=femoral flow/mean 
arterial pressure) was calculated using 1000 consecutive heart beats at baseline and 
following ganglionic antagonism with hexamethonium bromide (Hex; 25 mg/kg). The 
variability was modulated by both E2 and the sympathetic nervous system, but the reason 
for this variability is unknown. 
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Figure A.1 ‒ Representative raw data tracings of female (A, B, C) and male (D, E, F) 
spontaneously hypertensive rats. Note the large fluctuations in femoral flow (C) of 
female rat, with little or no change in arterial pressure (A), or heart rate (B). 
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Figure A.2 ‒ Coefficient of variation (CoV) for femoral conductance (CFem) amongst the 
experimental groups at baseline and following sympathectomy with hexamethonium 
bromide (Hex). * denotes P<0.05 versus baseline within-group; † denotes P<0.05 versus 
intact male at baseline. 
 
 
 
Chapter 5 ‒ Estrogen manipulation and vascular mechanics. 
Table A.1 ‒ The absolute in vivo hemodynamic variables from Wistar-Kyoto (WKY) and spontaneously hypertensive rats (SHR) that 
were either ovariectomized (OVX) or ovariectomized and supplemented with estrogen (OVX+E2). 
Strain Variable Intact OVX OVX+E 
WKY 
HR (beats/min) 345±29 399±20 327±23 
MAP (mmHg) 78±5 75±10 76±6 
QCaud (mL/min) 5.0±2.0 6.6±3.9 4.0±2.0 
CCond (mL/min/mmHg) 65±28 94±61 54±31 
SHR 
HR (beats/min) 381±38 340±43 390±33* 
MAP (mmHg) 103±19* 86±13 109±27* 
QCaud (mL/min) 3.5±1.6* 4.4±1.3 3.4±1.2 
CCond (mL/min/mmHg) 33±11* 51±12† 31±8‡ 
Values are mean ± Standard Deviation. HR = Heart Rate; MAP = Mean Arterial Pressure; QCond = Caudal Flow; CCond = Caudal 
Conductance; R = Resistance; C = Compliance; K = Viscoelasticity; PWV = Pulse Wave Velocity. * denotes P<0.05 versus WKY (of 
same group); † denotes P<0.05 versus Intact; ‡ denotes P<0.05 versus OVX.
149
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Figure A.3 ‒ Resistance (R), compliance (C), viscoelasticity (K) and pulse wave velocity 
(PWV) in intact, ovariectomized (OVX) and ovariectomized supplemented with estrogen 
(OVX+E2) Wistar Kyoto (WKY) and spontaneously hypertensive rats (SHR). Values are 
mean ± standard deviation. * denotes P<0.05 versus WKY of same group, † denotes 
P<0.05 versus OVX of same strain (both point to point comparisons). Main effect 
statistics: a, P<0.05 versus WKY; b, P<0.05 versus OVX. 
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Appendix C ‒ Details of Western Blot Protocol 
Approximately 70mg of frozen tissues were homogenized in 15 volumes 
(approximately 1 mL) of extraction buffer (10mM Tris, 100mM NaCl, 1mM EDTA, 
1mM EGTA Tetra Sodium, 1% Triton X-100, 10% Glycine, 0.1% SDS, 0.5% Sodium 
Deoxycholate, 1% protease inhibitor cocktail (Sigma-Aldrich, Cat. No. P8340); pH = 
7.4), and centrifuged at 16000g for 20 min in order to collect the supernatant as the tissue 
extract. Sample homogenates were then stored at −70°C until the time of total protein 
concentration determination (Bradford protein assay (1)) and electrophoresis.  Equal 
amounts of total protein (60 μg for Y1R and 120 μg for Tyrosine Hydroxylase (TH) and 
α-AR) were run on 12% sodium dodecyl sulfate polyacrylamide gel (SDS PAGE) 
overlaid with a 4% acrylamide stacking gel.  A protein standard (Bio-Rad Cat. No. 161-
0376) was run along with the tissue homogenate.  Following electrophoresis, the proteins 
were transferred at constant voltage in cold transfer buffer (10% running buffer, 20% 
methanol in ddH2O) to a polyvinylidene fluoride membrane (PVDF; Bio-Rad Cat. No. 
162-0177). The membranes were wetted with methanol prior to protein transfer, and 
subsequently blocked in a 5% non-fat milk solution in Tris buffered saline + 0.05% 
Tween 20 (TTBS) (80mM Tris Base, 0.5M NaCl). Membranes were then incubated 
overnight in primary antibody specific to either rat, human or mouse anti-Y1R (1:300, 
affinity purified rabbit anti-mouse Y1R IgG, Alpha Diagnostic International, Cat. No. 
NPY1R11-A, San Antonio, TX, USA), anti-α1-AR (1:400 affinity isolated rabbit, Sigma-
Aldrich Cat. No. A270) or anti-TH (1:1000 purified rabbit polyclonal antibody, 
Millipore, Cat. No. AB152, Billerica, MA, USA) in TTBS with 2% non-fat milk.  
Membranes were washed 3 times in TTBS then incubated in secondary antibody (goat 
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anti-rabbit, or anti-mouse; 1:3000) conjugated to horseradish peroxidase (HRP; Bio-Rad, 
Cat. No. 170-6518) and Precision Protein StrepTactin-HRP Conjugate (1:10000; Bio-
Rad, Cat.No. 161-0380) in TTBS with 2% non-fat milk for 1 hour. After washing (TTBS; 
3 times), the blots were developed using Immun-Star WesternC chemiluminescent (Bio-
Rad, Cat. No. 170-5070) and detected using a Bio-Rad ChemiDoc XRS system (Bio-Rad, 
Cat. No. 170-8070) with a supersensitive 16-bit CCD.  Images were analyzed using 
Quantity One 1-D Analysis Software (Bio-Rad, Cat. No. 170-9600).  
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2010 Carolyn tum Suden Professional Opportunity Award. From The American 
Physiological Society. $500. 
2009–10 Ontario Graduate Scholarship. From the Government of Ontario. 
$15,000/year. 
2009 American Physiological Society Travel Award. From The American 
Physiological Society. $625 
2009 Faculty of Health Sciences Travel Award. From The Faculty of Health 
Sciences, The University of Western Ontario. $500. 
2008–09 Ontario Graduate Scholarship. From the Government of Ontario. 
$15,000/year. 
2008 Faculty of Health Sciences Travel Award. From The Faculty of Health 
Sciences, The University of Western Ontario. $500. 
2008 Kinesiology Travel Award. From The School of Kinesiology, The University 
of Western Ontario. $625. 
2008 Society of Graduate Students Travel Subsidy. The Society of Graduate 
Students, The University of Western Ontario. $400. 
2008 Graduate Thesis Award. The University of Western Ontario. $544. 
2008 Mercury Printing Poster Award. From the Western Research Forum, The 
University of Western Ontario. $50. 
2004–06 Master’s Studentship Award. From The Heart and Stroke Foundation of 
Ontario. $18,000/year. 
Professional Membership 
The American Physiological Society 
The Canadian Society for Exercise Physiology 
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Professional Service 
a) Conference Organization 
2007 Canadian Society for Exercise Physiology (CSEP). The University of Western 
Ontario. 
2007 Ontario Exercise Physiology (OEP). The University of Western Ontario. 
2005 Ontario Exercise Physiology (OEP). University of Waterloo. 
b) Committee Involvement 
Graduate Student Level 
2009–10 President, The Kinesiology Graduate Board, The University of Western 
Ontario. 
2009–10 Member, Graduate Student Teaching Assistant Nomination Committee, The 
University of Western Ontario. 
2009–10 Member, Western Research Forum Committee, The University of Western 
Ontario. 
2008–09 Treasurer, The Kinesiology Graduate Board, The University of Western 
Ontario. 
Department/School Level 
2009–10 Graduate Student Member, Kinesiology Graduate Affairs Committee, The 
University of Western Ontario. 
2009–10 Graduate Student Member, Kinesiology Executive Management Committee, 
The University of Western Ontario. 
2007–10 Graduate Student Member, Kinesiology School Affairs Counsel, The 
University of Western Ontario. 
2005–06 Member, Kinesiology Graduate Student Association, University of 
Waterloo. 
Faculty Level 
2009–10 Graduate Student Member, Faculty of Health Sciences Faculty Counsel, The 
University of Western Ontario. 
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University Level 
2008–10 Counsellor, The Society of Graduate Students, The University of Western 
Ontario. 
2005–06 Member-At-Large, Graduate Student Association, University of Waterloo. 
Scholarly Activity 
Summary: 
Articles in Progress/Submitted: 5 
Articles in peer-reviewed journals: 6 
Published abstracts from professional meetings: 13 
Poster Presentations at Professional Meetings: 10 
Oral Presentations at Professional Meetings: 7 
Other Oral Presentations: 4 
 
a) Articles in Progress/Submitted: 
1. Mattar, L. D.N. Jackson and Shoemaker, J.K. (Submitted). Estrogen and 
sympathetic modulation of hindlimb blood flow variability in rats. To be submitted to 
Applied Physiology Nutrition and Metabolism APNM 11-4. 
2. Mattar, L., Gimon, T., Zamir, M., and J.K. Shoemaker (submitted previously). 
Sympathetic Contribution to Peripheral Vascular Stiffness in Young Female 
Spontaneously Hypertensive Rats.  
3. Mattar, L., Jackson, D.N., Ellis, C.G., Noble, E. and Shoemaker, J.K. (submitted 
previously). Age-related changes in sympathetic control of hindlimb conductance 
and blood pressure in young hypertensive rats.  
4. Mattar, L. and Shoemaker, J.K. (In Progress). Increased vascular stiffness in 
spontaneously hypertensive rats following estrogen supplementation. To be submitted 
to Clinical and Experimental Pharmacology and Physiology.  
5. Mattar, L., Zamir, M., and J.K. Shoemaker (In Progress). Y1 Receptor versus 
sympathetic control of hindlimb vascular stiffness in spontaneously hypertensive rats. 
To be submitted to AJP - Reg. Int. Comp. Phys. 
b) Articles in peer-reviewed journals: 
1. Usselman, C.W., Mattar, L., Junuzovic, J., Welch, I., and Shoemaker, J.K. 
(Accepted). Intra-strain baroreflex variability in urethane/α-chloralose anaesthetized 
male Sprague-Dawley rats. Applied Physiology Nutrition and Metabolism, APNM-
10-264.  
2. Hodges, G.J., Mattar, L., Zuj, K, Greaves, D., Arbeille, P., Hughson, R.L., and 
Shoemaker, J.K. (2010). WISE 2005: Prolongation of left ventricular pre-ejection 
period with 56 days head-down bed rest in women. Experimental Physiology, 95(11): 
1081. 
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3. Hodges, G.J., Jackson, D.N., Mattar, L., Johnson, J., and Shoemaker, J.K. (2009). 
Neuropeptide Y and neurovascular control in skeletal muscle and skin. AJP – 
Regulatory, Integrative and Comparative Physiology. 297: R546-R555. 
4. Arbeille, P., Kerbeci, P., Mattar, L., Shoemaker, J.K., and Hughson, R.L. (2008). 
Insufficient flow reductions during LBNP in both splanchnic and lower limbs is 
associated with orthostatic intolerance after bedrest. AJP – Heart and Circulatory 
Physiology. 295: H1846 - H1845. 
5. Arbeille, P., Kerbeci, P., Mattar, L., Shoemaker, J.K., and Hughson, R.L. (2008). 
WISE-2005 – Tibial and Gastrocnemius Vein, and Calf Tissue Response to LBNP 
after a 60 day Bedrest with and without Counter-measures. Journal of Applied 
Physiology. 104: 938-943. 
6. Shoemaker, J.K., Mattar, L., Kerbeci, P., Trotter, S., Arbeille, P., Hughson, R.L. 
(2007). WISE 2005: Stroke Volume Changes Contribute to the Pressor Response 
During Ischemic Handgrip Exercise in Females. Journal of Applied Physiology. 103: 
228 - 233. 
c) Published abstracts from professional meetings: 
1. Mattar, L., Gimon, T., Zamir, M., and J.K. Shoemaker (2010). Vascular stiffness and 
the sympathetic nervous system in young female rats. APNM, 35:S65. 
2. Mattar L., Noble, E., and Shoemaker, J.K. (2010). Estrogen and sympathetic 
modulation of hindlimb blood flow variability in rats. FASEB Journal. 24:1039.13.  
3. Mattar L., Jackson, D.N., Ellis, C.G., Noble, E., and Shoemaker, J.K. (2009). Beta-
arrestin and vasomotor control in the spontaneously hypertensive rat. FASEB Journal. 
23:1017.45. 
4. Usselman, C.W., Welch, I., Mattar, L., and Shoemaker, J.K. (2009). Effect of depth 
of anaesthesia and postganglionic sympathetic blockade on reflex heart rate control in 
rodents during lower body negative pressure. FASEB Journal. 23:609.11. 
5. Mattar L., Jackson, D.N., and Shoemaker, J.K. (2008). Neuropeptide Y And Age-
Related Development of Hypertension in the Rat. FASEB Journal. 22:968.18. 
6. Edgell, H., Greaves, D., Mattar, L., Arbeille, P., Custaud, M.A., and Hughson, R.L. 
(2008). WISE-2005: Changes in cardiovascular variables due to increasing levels of 
adrenergic stimulation in women according to phase of menstruation. Committee on 
Space Research. 
7. Hughson, R.L., Shoemaker, J.K., Arbeille, P., Dyson, K.S., Edgell, H., Kerbeci, P., 
Mattar, L., Zuj, K., and Greaves, D.K. (2007). WISE-2005: Vascular Responses to 
60-Day Bed Rest. Journal of Gravitational Physiology. 
8. Shoemaker, J.K., Arbeille, P., Kerbeci, P., Mattar, L., and Hughson, R.L. (2007). 
WISE-2005: Impact of 60-Day Bed Rest on Ischemic Exercise Pressor Response in 
Females. Journal of Gravitational Physiology. 
9. Hughson, R.L., Kerbeci, P., Arbeille, P., Mattar, L., and Shoemaker, J.K. (2006). 
WISE-2005: Integrative Cardiovascular Responses with LBNP During 60-Day Bed 
Rest in Women. Journal of Gravitational Physiology. 
10. Shoemaker, J.K., Mattar, L., Kerbeci, P., Trotter, S., Arbeille, P., and Hughson, R.L. 
(2006). WISE 2005: pressor responses to fatiguing handgrip are related to cardiac 
output and not to systemic vascular resistance APNM, 31:S79. 
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11. Shoemaker, J.K., Mattar, L., Kerbeci, P., Trotter, S., Arbeille, P., Hughson, R.L. 
(2006). WISE 2005: Does Cardiac Output Contribute to The Pressor Response 
During Isometric Handgrip Exercise in Humans? Medicine & Science in Sports & 
Exercise. 38(11) Suppl 1:S17. 
12. Mattar, L., Rush, J.W.E., Shoemaker, J.K., Arbeille, P., and Hughson, R.L. (2006). 
WISE-2005: 60 days head-down bed rest causes a shift towards a pro-artherosclerotic 
environment. FASEB Journal, 20(5):A1254. 
13. Mattar, L., Rush, J.W.E., Shoemaker, J.K., Arbeille, P., and Hughson, R.L. (2005). 
WISE-2005: 60 Days Head-Down Bed Rest Causes and Increase in Angiotensin II. 
Canadian Journal of Applied Physiology 30:S53. 
d) Poster Presentations at Professional Meetings: 
1. Mattar, L., Gimon, T., Zamir, M., and J.K. Shoemaker (2010). Vascular stiffness and 
the sympathetic nervous system in young female rats. The Canadian Society for 
Exercise Physiology; Toronto, ON; November 2010. 
2. Mattar L., Noble, E., and Shoemaker, J.K. (2010). Estrogen and sympathetic 
modulation of hindlimb blood flow variability in rats. Experimental Biology; 
Anaheim, CA; April 2010. 
3. Mattar L., Jackson, D.N., Ellis, C.G., Noble, E., and Shoemaker, J.K. (2009). Beta-
arrestin and vasomotor control in the spontaneously hypertensive rat. J. Allen Taylor 
International Prize in Medicine: Cardiovascular Research; London, Ontario; 
November 2009.  
4. Mattar, L., Noble, E., Shoemaker, J.K. (2009). Estrogen and the development of 
hypertension in the female spontaneously hypertensive rats. APS Conference: Sex and 
Gender in Cardiovascular-Renal Physiology and Pathophysiology; Broomfield, CO; 
July 2009. 
5. Mattar L., Jackson, D.N., Ellis, C.G., Noble, E., and Shoemaker, J.K. (2009). Beta-
arrestin and vasomotor control in the spontaneously hypertensive rat. Experimental 
Biology; New Orleans, LA; April 2009. 
6. Mattar L., Jackson, D.N. and Shoemaker, J.K. (2008). Neuropeptide Y And Age-
Related Development of Hypertension in the Rat. Experimental Biology; Dan Diego, 
CA; April 2008. 
7. Mattar L., Jackson, D.N. and Shoemaker, J.K. (2008). Neuropeptide Y And Age-
Related Development of Hypertension in the Rat. Western Research Forum; London, 
ON; February 2008.  
8. Mattar L., Jackson, D.N. and Shoemaker, J.K. (2008). Enhanced Constrictor 
Response to Neuropeptide Y in the 7 week old Rat. ARGC/FHS Symposium on aging; 
London, ON; February 2008. 
9. Mattar, L., Rush, J.W.E., Shoemaker, J.K., Arbeille, P., and Hughson., R.L. (2006). 
WISE-2005: 60 days head-down bed rest causes a shift towards a pro-artherosclerotic 
environment. Experimental Biology; San Francisco, CA; April 2006. 
10. Mattar, L.; Rush, J.W.E., Shoemaker, J.K., Arbeille, P., and Hughson, R.L. (2005). 
WISE-2005: 60 Days Head-Down Bed Rest Causes and Increase in Angiotensin II. 
Canadian Society for Exercise Physiology; Gatineau, QC; November 2005. 
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e) Oral presentations at Professional Meetings: 
1. Mattar, L. and Shoemaker, J.K. (2011). Sexual dimorphism and cardiovascular 
regulation in rats. Western Research Forum; London, ON; February 2011. 
2. Mattar, L. and Shoemaker, J.K. (2011). Evidence for sexual dimorphism in 
cardiovascular regulation in rats. Ontario Exercise Physiology; Barrie, ON; January 
2010. 
3. Mattar, L., Jackson, D.N., Noble, E., and Shoemaker, J.K. (2010). Modulation of 
hindlimb blood flow variability by estrogen and the sympathetic nervous system in 
rats. Ontario Exercise Physiology; Barrie, ON; January 2010. 
4. Mattar, L., Jackson, D.N., Ellis, C.G., Noble, E., and Shoemaker, J.K. (2009). Beta-
arrestin and vascular control in hypertension. Western Research Forum; London, ON; 
January 2009. 
5. Mattar, L., Jackson, D.N., and Shoemaker, J.K. (2009). Neuropeptide Y And Age-
Related Development of Hypertension in the Rat. Ontario Exercise Physiology; 
Barrie, ON; January 2009. 
6. Mattar, L., Jackson, D.N., and Shoemaker, J.K. (2008). Enhanced Constrictor 
Response to Neuropeptide Y in the Spontaneously Hypertensive Rat. Ontario 
Exercise Physiology; Barrie, ON; January 2008. 
7. Mattar, L., Rush, J.W.E., Shoemaker, J.K., Arbeille, P., and Hughson, R.L. (2006). 
WISE 2005: 60 Days Head down bed rest causes an increase in oxidative stress. 
Ontario Exercise Physiology; Barrie, ON; January 2006. 
f) Other Oral Presentations: 
1. Presentation for Mrs. Kelly Sauve Grade 12 University Biology Preparation class. “A 
career in school: Options for after University”. Dorchester High School; Dorchester, 
ON; December 2008. 
2. Lecture for Dr. H. Prapavessis 2nd/3rd year statistics (KIN 332a). The University of 
Western Ontario. London, ON; October 2007. 
3. Presentation for Ms. Jan Farquhar Grade 8 gifted class. “Why I like science”. Charles 
R. Beaudoin Public School; Oakville, ON; June 2007. 
4. Lecture for Dr. Timothy Wilson 2nd/3rd year anatomy. Anatomy of the Heart and 
Lungs. The University of Western Ontario; London, ON; November 2006. 
 
 
